<?xml version="1.0" encoding="UTF-8"?>
<search_results count="7464">
  <!--<query>COVID-19</query>-->
  <!-- Additional study fields may be added over time -->
  <study rank="1">
    <nct_id>NCT04372602</nct_id>
    <title>Duvelisib to Combat COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Duvelisib</intervention>
      <intervention type="Procedure">Peripheral blood draw</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>Duration of ventilator use</outcome_measure>
      <outcome_measure>Duration of vasopressors use</outcome_measure>
      <outcome_measure>Duration on renal replacement therapy</outcome_measure>
      <outcome_measure>Viral kinetics as measured by virologic failure</outcome_measure>
      <outcome_measure>Number of adverse events as measured by CTCAE v. 5.0</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>Verastem, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>202007009</other_id>
    </other_ids>
    <start_date>October 12, 2020</start_date>
    <primary_completion_date>November 30, 2021</primary_completion_date>
    <completion_date>April 30, 2022</completion_date>
    <study_first_posted>May 4, 2020</study_first_posted>
    <last_update_posted>May 25, 2021</last_update_posted>
    <locations>
      <location>Missouri Baptist Medical Center, Saint Louis, Missouri, United States</location>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04372602</url>
  </study>
  <study rank="2">
    <nct_id>NCT04902157</nct_id>
    <title>Relationship Between CT- Value With Prognosis in COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Cycle threshold</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>prognosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>SBMU.34.675</other_id>
    </other_ids>
    <start_date>February 1, 2021</start_date>
    <primary_completion_date>January 1, 2022</primary_completion_date>
    <completion_date>February 1, 2022</completion_date>
    <study_first_posted>May 26, 2021</study_first_posted>
    <last_update_posted>May 26, 2021</last_update_posted>
    <locations>
      <location>SBMU, Tehran, Iran, Islamic Republic of</location>
      <location>Nooshin Dalili, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04902157</url>
  </study>
  <study rank="3">
    <nct_id>NCT04364698</nct_id>
    <title>Observational Cohort of COVID-19 Patients at Raymond-Poincare</title>
    <acronym>COVID-RPC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>clinical, biological and radiological characteristics</outcome_measure>
      <outcome_measure>patients' journey description</outcome_measure>
      <outcome_measure>Treatments effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>20SBS-COVID-RPC</other_id>
    </other_ids>
    <start_date>May 7, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>May 14, 2020</last_update_posted>
    <locations>
      <location>Department of Infectiology, Raymond Poincaré Hospital, APHP, Garches, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364698</url>
  </study>
  <study rank="4">
    <nct_id>NCT04459637</nct_id>
    <title>COVID-19 Surveillance Based on Smart Wearable Device</title>
    <acronym>COVID-19SWD</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Deterioration of the condition</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>The information analysis degree, the proportion of signal loss, the proportion of wrong signal,</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking University First Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2020055-0615</other_id>
    </other_ids>
    <start_date>July 1, 2020</start_date>
    <primary_completion_date>March 10, 2021</primary_completion_date>
    <completion_date>March 10, 2021</completion_date>
    <study_first_posted>July 7, 2020</study_first_posted>
    <last_update_posted>July 7, 2020</last_update_posted>
    <locations>
      <location>Peking University First Hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04459637</url>
  </study>
  <study rank="5">
    <nct_id>NCT04425538</nct_id>
    <title>A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Improvement in Oxygenation</outcome_measure>
      <outcome_measure>Incidence of Improvement in Oxygenation</outcome_measure>
      <outcome_measure>28-Day Survival Status</outcome_measure>
      <outcome_measure>Duration of Supplemental Oxygen Administration by Nasal Cannula</outcome_measure>
      <outcome_measure>Duration of Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula</outcome_measure>
      <outcome_measure>Incidence of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Incidence of Vasopressor Support</outcome_measure>
      <outcome_measure>Incidence of Extracorporeal Membrane Oxygenation</outcome_measure>
      <outcome_measure>Incidence of Fever</outcome_measure>
      <outcome_measure>Correlation of Cytokine Profile to Clinical Outcomes Specified in Primary and Secondary Objectives</outcome_measure>
      <outcome_measure>Duration of Hospitalization</outcome_measure>
      <outcome_measure>Incidence of Secondary Infections</outcome_measure>
      <outcome_measure>Incidence of Supplemental Oxygen Administration by Nasal Cannula</outcome_measure>
      <outcome_measure>Duration of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Incidence of Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula</outcome_measure>
      <outcome_measure>Assessment of Cytokine and Inflammatory Profile at Baseline and at 48 Hours After Therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tufts Medical Center</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY00000564</other_id>
    </other_ids>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>January 22, 2021</primary_completion_date>
    <completion_date>January 22, 2021</completion_date>
    <study_first_posted>June 11, 2020</study_first_posted>
    <results_first_posted>December 3, 2021</results_first_posted>
    <last_update_posted>December 3, 2021</last_update_posted>
    <locations>
      <location>Tufts Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT04425538/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04425538</url>
  </study>
  <study rank="6">
    <nct_id>NCT05175846</nct_id>
    <title>INFLAMmatory BiomarkErs in COVID-19 Participants and Severity of Disease</title>
    <acronym>INFLAME COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To identify immunological and inflammatory biomarkers in participants with and without COVID-19 that may predict a participant's potential risk for severity of disease.</outcome_measure>
      <outcome_measure>To correlate the biomarkers at baseline with the duration of symptoms up to six months in participants who develop COVID-19.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Trinitas Global, LLC</lead_sponsor>
      <collaborator>AccessDx Laboratories, Houston, TX</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>001</other_id>
    </other_ids>
    <start_date>January 2022</start_date>
    <primary_completion_date>June 30, 2022</primary_completion_date>
    <completion_date>January 31, 2023</completion_date>
    <study_first_posted>January 4, 2022</study_first_posted>
    <last_update_posted>January 19, 2022</last_update_posted>
    <locations>
      <location>St Francis Hospital, Wilmington, Delaware, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05175846</url>
  </study>
  <study rank="7">
    <nct_id>NCT05003271</nct_id>
    <title>Pulmonary Rehabilitation Post-COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Exercise program (virtual/remote)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in lung capacity</outcome_measure>
      <outcome_measure>Change in dyspnea</outcome_measure>
      <outcome_measure>Change in fatigue</outcome_measure>
      <outcome_measure>Change in exercise capacity</outcome_measure>
      <outcome_measure>Change in post-exercise saturation</outcome_measure>
      <outcome_measure>Change in physical function</outcome_measure>
      <outcome_measure>Change in activities participation</outcome_measure>
      <outcome_measure>Changes in health-related quality of life (HRQoL) assessed with the EQ-5D-5L</outcome_measure>
      <outcome_measure>Changes in health-related quality of life (HRQoL) assessed with the Short form (SF)-36 questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Manitoba</lead_sponsor>
      <collaborator>Health Sciences Centre Foundation, Manitoba</collaborator>
      <collaborator>Health Sciences Centre, Winnipeg, Manitoba</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HS25183(B2021:101)</other_id>
    </other_ids>
    <start_date>October 2021</start_date>
    <primary_completion_date>May 2022</primary_completion_date>
    <completion_date>July 2022</completion_date>
    <study_first_posted>August 12, 2021</study_first_posted>
    <last_update_posted>October 7, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05003271</url>
  </study>
  <study rank="8">
    <nct_id>NCT04547257</nct_id>
    <title>Safety &amp; Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19</title>
    <acronym>CP022</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Seraph 100</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Organ failure</outcome_measure>
      <outcome_measure>Change in Organ Failure</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Organ dysfunction-free days</outcome_measure>
      <outcome_measure>Intensive Care Unit (ICU) complications</outcome_measure>
      <outcome_measure>Ventilator-free days (VFDs)</outcome_measure>
      <outcome_measure>Length of stay (LOS) at ICU and hospital ward</outcome_measure>
      <outcome_measure>Prognosis Factors</outcome_measure>
      <outcome_measure>Recurrence of sepsis</outcome_measure>
      <outcome_measure>Persistence of sepsis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ExThera Medical Europe BV</lead_sponsor>
      <collaborator>ExThera Medical Corporation</collaborator>
      <collaborator>Vivantes Klinikum Neukölln</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CP022</other_id>
    </other_ids>
    <start_date>May 4, 2021</start_date>
    <primary_completion_date>July 31, 2022</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>September 14, 2020</study_first_posted>
    <last_update_posted>January 6, 2022</last_update_posted>
    <locations>
      <location>Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany</location>
      <location>Vivantes Klinikum Neukölln, Berlin, Germany</location>
      <location>Universitätsklinikum Essen, Essen, Germany</location>
      <location>Hospital Universitari Vall d'Hebron, Barcelona, Spain</location>
      <location>Hospital Clinico San Carlos, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04547257</url>
  </study>
  <study rank="9">
    <nct_id>NCT04454307</nct_id>
    <title>Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tramadol</intervention>
      <intervention type="Other">Standard care delivered in the isolation hospitals.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of COVID-19 PCR negative cases</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TRAM/COVID19</other_id>
    </other_ids>
    <start_date>July 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>July 1, 2020</study_first_posted>
    <last_update_posted>July 2, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04454307</url>
  </study>
  <study rank="10">
    <nct_id>NCT04452435</nct_id>
    <title>Safety and Efficacy of C21 in Subjects With COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">C21</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.)</outcome_measure>
      <outcome_measure>Change From Baseline in Body Temperature</outcome_measure>
      <outcome_measure>Change From Baseline in IL-6</outcome_measure>
      <outcome_measure>Change From Baseline in IL-10</outcome_measure>
      <outcome_measure>Change From Baseline in TNF</outcome_measure>
      <outcome_measure>Change From Baseline in CA125</outcome_measure>
      <outcome_measure>Change From Baseline in Ferritin</outcome_measure>
      <outcome_measure>Number of Subjects Not in Need of Oxygen Supply</outcome_measure>
      <outcome_measure>Number of Subjects Not in Need of Mechanical Invasive or Non-invasive Ventilation</outcome_measure>
      <outcome_measure>Time to Need of Mechanical Invasive or Non-invasive Ventilation</outcome_measure>
      <outcome_measure>Time on Oxygen Supply (for Those Not Needing Mechanical Invasive or Non-invasive Ventilation)</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vicore Pharma AB</lead_sponsor>
      <collaborator>Orphan Reach</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>206</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>VP-C21-006</other_id>
      <other_id>2020-001502-38</other_id>
    </other_ids>
    <start_date>July 21, 2020</start_date>
    <primary_completion_date>October 13, 2020</primary_completion_date>
    <completion_date>October 13, 2020</completion_date>
    <study_first_posted>June 30, 2020</study_first_posted>
    <results_first_posted>April 30, 2021</results_first_posted>
    <last_update_posted>June 23, 2021</last_update_posted>
    <locations>
      <location>Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India</location>
      <location>Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India</location>
      <location>Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India</location>
      <location>First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India</location>
      <location>Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India</location>
      <location>Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India</location>
      <location>Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India</location>
      <location>Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India</location>
      <location>Respiratory Medicine, University College Hospital, London, United Kingdom</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan: Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT04452435/Prot_SAP_000.pdf</url>
      </study_document>
      <study_document>
        <label>Statistical Analysis Plan: Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT04452435/SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04452435</url>
  </study>
  <study rank="11">
    <nct_id>NCT04333550</nct_id>
    <title>Application of Desferal to Treat COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Deferoxamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>change in patients clinical manifestation</outcome_measure>
      <outcome_measure>change in patients PaO2</outcome_measure>
      <outcome_measure>Length of hospitalization</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>lymphocyte count</outcome_measure>
      <outcome_measure>length of intensive care unit stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kermanshah University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1398.1224</other_id>
    </other_ids>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>May 4, 2020</last_update_posted>
    <locations>
      <location>Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333550</url>
  </study>
  <study rank="12">
    <nct_id>NCT04432987</nct_id>
    <title>Dornase Alpha for the Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pulmozyme</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Response</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Acibadem University</lead_sponsor>
      <collaborator>The Scientific and Technological Research Council of Turkey</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>8820</other_id>
    </other_ids>
    <start_date>May 25, 2020</start_date>
    <primary_completion_date>August 25, 2020</primary_completion_date>
    <completion_date>September 25, 2020</completion_date>
    <study_first_posted>June 16, 2020</study_first_posted>
    <last_update_posted>June 16, 2020</last_update_posted>
    <locations>
      <location>Acıbadem Altunizade Hospital, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04432987</url>
  </study>
  <study rank="13">
    <nct_id>NCT04537559</nct_id>
    <title>Impact of COVID-19 Outbreak on Non-COVID-19 Patients</title>
    <acronym>NoCOVImpact</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Intra-hospital mortality</outcome_measure>
      <outcome_measure>composite outcome (worsening during hospitalization)</outcome_measure>
      <outcome_measure>Pathologies leading to hospitalization</outcome_measure>
      <outcome_measure>overall mortality at 3 months (90 days)</outcome_measure>
      <outcome_measure>Potentially avoidable readmission rate</outcome_measure>
      <outcome_measure>mortality rate by pathology at 3 months</outcome_measure>
      <outcome_measure>length of stay</outcome_measure>
      <outcome_measure>rate of transfer to intermediate or intensive care</outcome_measure>
      <outcome_measure>rate of transfer to rehabilitation care</outcome_measure>
      <outcome_measure>specific gravity outcomes for patients with pneumonia : CURB 65 scale (Confusion, Urea, Respiratory rate, Blood pressure, Age [&gt;65])</outcome_measure>
      <outcome_measure>specific gravity outcomes for patients with cardiac Failure : KILLIP class</outcome_measure>
      <outcome_measure>specific gravity outcomes for patients with cardiac Failure : Weight variation</outcome_measure>
      <outcome_measure>specific gravity outcomes for patients with cardiac Failure or lung disease</outcome_measure>
      <outcome_measure>Leukocytes serum level</outcome_measure>
      <outcome_measure>Polynuclear neutrophils serum level</outcome_measure>
      <outcome_measure>Lymphocytes serum level</outcome_measure>
      <outcome_measure>Hemoglobin serum level</outcome_measure>
      <outcome_measure>Thrombocytes serum level</outcome_measure>
      <outcome_measure>Quick serum level</outcome_measure>
      <outcome_measure>INR (International Normalized Ratio)</outcome_measure>
      <outcome_measure>fibrinogen serum level</outcome_measure>
      <outcome_measure>PTT serum level (partial Thromboplastin time)</outcome_measure>
      <outcome_measure>D-Dimers serum level</outcome_measure>
      <outcome_measure>glucose serum level</outcome_measure>
      <outcome_measure>glycated hemoglobin serum level (HbA1C)</outcome_measure>
      <outcome_measure>C-reactive protein serum level (CRP)</outcome_measure>
      <outcome_measure>sodium serum level</outcome_measure>
      <outcome_measure>potassium serum level</outcome_measure>
      <outcome_measure>chlorides serum level</outcome_measure>
      <outcome_measure>calculated osmolality serum level</outcome_measure>
      <outcome_measure>Phosphates serum level</outcome_measure>
      <outcome_measure>corrected calcium serum level</outcome_measure>
      <outcome_measure>urea serum level</outcome_measure>
      <outcome_measure>creatinine serum level</outcome_measure>
      <outcome_measure>eGFR (CKD-EPI) serum level</outcome_measure>
      <outcome_measure>albumin serum level</outcome_measure>
      <outcome_measure>prealbumin serum level</outcome_measure>
      <outcome_measure>cyanocobalamin serum level</outcome_measure>
      <outcome_measure>folate serum level</outcome_measure>
      <outcome_measure>25-hydroxy vitamin D (D2 + D3) serum level</outcome_measure>
      <outcome_measure>proBNP (Brain Natriuretic Peptid) serum level</outcome_measure>
      <outcome_measure>Ultra sensitive Troponin T serum level</outcome_measure>
      <outcome_measure>ASAT (aspartate transaminase) serum level</outcome_measure>
      <outcome_measure>ALAT (alanine aminotransferase) serum level</outcome_measure>
      <outcome_measure>Alkaline phosphatases serum level</outcome_measure>
      <outcome_measure>Gamma glutamyl transpeptidase. serum level</outcome_measure>
      <outcome_measure>Total bilirubin serum level</outcome_measure>
      <outcome_measure>ferritin serum level</outcome_measure>
      <outcome_measure>TSH serum level</outcome_measure>
      <outcome_measure>Arterial pH</outcome_measure>
      <outcome_measure>Arterial pCO2 (carbon dioxide partial pressure)</outcome_measure>
      <outcome_measure>Arterial pO2 (oxygen partial pressure)</outcome_measure>
      <outcome_measure>Arterial lactate</outcome_measure>
      <outcome_measure>Arterial HCO3 (bicarbonate)</outcome_measure>
      <outcome_measure>protein serum level</outcome_measure>
      <outcome_measure>Arterial pressure</outcome_measure>
      <outcome_measure>cardiac rates</outcome_measure>
      <outcome_measure>respiratory rates</outcome_measure>
      <outcome_measure>temperature</outcome_measure>
      <outcome_measure>oxygen saturation</outcome_measure>
      <outcome_measure>peak flow</outcome_measure>
      <outcome_measure>specific scales : VAS of pain</outcome_measure>
      <outcome_measure>specific scales : FIM</outcome_measure>
      <outcome_measure>specific scales : SOFA score</outcome_measure>
      <outcome_measure>specific scales : MNA</outcome_measure>
      <outcome_measure>specific scales : NRS</outcome_measure>
      <outcome_measure>serum or urine positive bacteriologic sample</outcome_measure>
      <outcome_measure>Patient questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
      <collaborator>Thomas Agoritsas</collaborator>
      <collaborator>Sebastian Carballo</collaborator>
      <collaborator>Pauline Darbellay</collaborator>
      <collaborator>Olivier Grosgurin</collaborator>
      <collaborator>Christophe Marti</collaborator>
      <collaborator>Mathieu Nendaz</collaborator>
      <collaborator>Jean-Luc Reny</collaborator>
      <collaborator>Jacques Serratrice</collaborator>
      <collaborator>Aimad Ourahmoune</collaborator>
      <collaborator>Delphine Courvoisier</collaborator>
      <collaborator>Virginie Prendki</collaborator>
      <collaborator>Christine Serratrice</collaborator>
      <collaborator>Dina Zekry</collaborator>
      <collaborator>Omar Kherad</collaborator>
      <collaborator>Eric Gerstel</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2020-01017</other_id>
    </other_ids>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>September 3, 2020</study_first_posted>
    <last_update_posted>September 7, 2020</last_update_posted>
    <locations>
      <location>Geneva University Hospital, Geneva, Canton De Genève, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04537559</url>
  </study>
  <study rank="14">
    <nct_id>NCT04628143</nct_id>
    <title>A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nafamostat Mesilate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Time to recovery</outcome_measure>
      <outcome_measure>Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chong Kun Dang Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>A108_01CVD2013</other_id>
    </other_ids>
    <start_date>December 21, 2020</start_date>
    <primary_completion_date>April 5, 2021</primary_completion_date>
    <completion_date>April 5, 2021</completion_date>
    <study_first_posted>November 13, 2020</study_first_posted>
    <last_update_posted>August 13, 2021</last_update_posted>
    <locations>
      <location>Korea Cancer Center Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04628143</url>
  </study>
  <study rank="15">
    <nct_id>NCT04869228</nct_id>
    <title>A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GT0918 tablets or placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of subjects requiring oxygen by Day 28</outcome_measure>
      <outcome_measure>Percentage of subjects who experience the events(such as hospitalization,Death etc.) by Day 28. (not applicable for subjects whose countries require mild to moderate COVID-19 patients to be hospitalised, such as COVID-19 patients in mainland China)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Suzhou Kintor Pharmaceutical Inc,</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>724</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GT0918-MR-3001</other_id>
    </other_ids>
    <start_date>August 4, 2021</start_date>
    <primary_completion_date>February 28, 2022</primary_completion_date>
    <completion_date>May 30, 2022</completion_date>
    <study_first_posted>May 3, 2021</study_first_posted>
    <last_update_posted>October 19, 2021</last_update_posted>
    <locations>
      <location>Hospital Santa Paula, São Paulo, SP, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04869228</url>
  </study>
  <study rank="16">
    <nct_id>NCT04568031</nct_id>
    <title>Study of AZD1222 for the Prevention of COVID-19 in Japan</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AZD1222</intervention>
      <intervention type="Drug">0.9% (w/v) saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222</outcome_measure>
      <outcome_measure>The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination</outcome_measure>
      <outcome_measure>The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)</outcome_measure>
      <outcome_measure>Biochemistry; change from baseline for blood chemistry measures</outcome_measure>
      <outcome_measure>Haematology; change from baseline for hematology/hemostasis measures</outcome_measure>
      <outcome_measure>Proportion of participants who have a post treatment</outcome_measure>
      <outcome_measure>Genometric mean titres and genometric mean fold rise</outcome_measure>
      <outcome_measure>Proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs</outcome_measure>
      <outcome_measure>The incidence of serious adverse events (SAEs) and adverse events of specisl interest (AESIs) collected from Day1 through Day365</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>Iqvia Pty Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>256</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>D8111C00002</other_id>
    </other_ids>
    <start_date>August 23, 2020</start_date>
    <primary_completion_date>November 22, 2021</primary_completion_date>
    <completion_date>November 22, 2021</completion_date>
    <study_first_posted>September 29, 2020</study_first_posted>
    <last_update_posted>November 30, 2021</last_update_posted>
    <locations>
      <location>Research Site, Fukuoka-shi, Japan</location>
      <location>Research Site, Hachioji-shi, Japan</location>
      <location>Research Site, Minato-ku, Japan</location>
      <location>Research Site, Sumida-ku, Japan</location>
      <location>Research Site, Toshima-ku, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04568031</url>
  </study>
  <study rank="17">
    <nct_id>NCT04336904</nct_id>
    <title>Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time from randomization to clinical recovery</outcome_measure>
      <outcome_measure>Time from randomization to negativity in RT-PCR nucleic acid test</outcome_measure>
      <outcome_measure>Incidence of deterioration/aggravation of pneumonia</outcome_measure>
      <outcome_measure>Time from randomization to resolution of pyrexia</outcome_measure>
      <outcome_measure>Time from randomization to relief of cough</outcome_measure>
      <outcome_measure>Time from randomization to relief of dyspnoea</outcome_measure>
      <outcome_measure>Rate of auxiliary oxygen therapy</outcome_measure>
      <outcome_measure>ICU admission rate</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Giuliano Rizzardini</lead_sponsor>
      <collaborator>ASST Fatebenefratelli Sacco</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HS216C17-PHASE III</other_id>
    </other_ids>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Asst Fatebenefratelli Sacco, Milano, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336904</url>
  </study>
  <study rank="18">
    <nct_id>NCT05074394</nct_id>
    <title>Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection</title>
    <acronym>US</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">COVI-DROPS</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who have a COVID-19-related visit or hospitalization</outcome_measure>
      <outcome_measure>Viral load change from baseline to Day 15 (D15)</outcome_measure>
      <outcome_measure>Proportion of subjects who have a COVID-19-related visit or hospitalization based on stratification groups</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sorrento Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DRP-COV-206US</other_id>
    </other_ids>
    <start_date>November 2021</start_date>
    <primary_completion_date>November 2022</primary_completion_date>
    <completion_date>January 2023</completion_date>
    <study_first_posted>October 12, 2021</study_first_posted>
    <last_update_posted>February 3, 2022</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05074394</url>
  </study>
  <study rank="19">
    <nct_id>NCT04354831</nct_id>
    <title>A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">anti-SARS-CoV-2 convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall Mortality within 60 days</outcome_measure>
      <outcome_measure>Length of ICU stay during current admission for COVID</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>Froedtert Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO00037712</other_id>
    </other_ids>
    <start_date>May 11, 2020</start_date>
    <primary_completion_date>May 1, 2022</primary_completion_date>
    <completion_date>May 1, 2023</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>November 15, 2021</last_update_posted>
    <locations>
      <location>Froedtert Hospital, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354831</url>
  </study>
  <study rank="20">
    <nct_id>NCT04582266</nct_id>
    <title>PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PK Outcome: Area under the plasma concentration-time curve (AUC) of RDV</outcome_measure>
      <outcome_measure>PK Outcome: Half-life (t1/2) of RDV</outcome_measure>
      <outcome_measure>PK Outcome: Trough concentration (Ctrough) of GS-441524</outcome_measure>
      <outcome_measure>Safety Outcome: Maternal renal adverse event (AE) of any grade</outcome_measure>
      <outcome_measure>Safety Outcome: Maternal hepatic AE of any grade</outcome_measure>
      <outcome_measure>Safety Outcome: Maternal hematologic AE of any grade</outcome_measure>
      <outcome_measure>Safety Outcome: Maternal Grade 3 or higher AE</outcome_measure>
      <outcome_measure>Safety Outcome: Serious AE</outcome_measure>
      <outcome_measure>Safety Outcome: Maternal Grade 3 or higher AE assessed as related to RDV by the Clinical Management Committee (CMC)</outcome_measure>
      <outcome_measure>Safety Outcome: Pregnancy loss</outcome_measure>
      <outcome_measure>Safety Outcome: Congenital anomalies</outcome_measure>
      <outcome_measure>Safety Outcome: Preterm birth, defined as &lt; 37 weeks</outcome_measure>
      <outcome_measure>Safety Outcome: Preterm birth, defined as &lt; 34 weeks</outcome_measure>
      <outcome_measure>Safety Outcome: Small for gestational age, defined as &lt; 10th percentile</outcome_measure>
      <outcome_measure>Safety Outcome: Newborn birth weight</outcome_measure>
      <outcome_measure>Safety Outcome: Newborn length</outcome_measure>
      <outcome_measure>Safety Outcome: Newborn head circumference</outcome_measure>
      <outcome_measure>PK Outcome: AUC of RDV</outcome_measure>
      <outcome_measure>PK Outcome: t1/2 of RDV</outcome_measure>
      <outcome_measure>PK Outcome: Ctrough of GS-441524</outcome_measure>
      <outcome_measure>Safety Outcome: Renal AE of any grade</outcome_measure>
      <outcome_measure>Safety Outcome: Hepatic AE of any grade</outcome_measure>
      <outcome_measure>Safety Outcome: Hematologic AE of any grade</outcome_measure>
      <outcome_measure>Safety Outcome: Grade 3 or higher AE</outcome_measure>
      <outcome_measure>Safety Outcome: Grade 3 or higher AE assessed as related to RDV by the CMC</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IMPAACT 2032</other_id>
      <other_id>DAIDS Study ID 38746</other_id>
    </other_ids>
    <start_date>February 12, 2021</start_date>
    <primary_completion_date>April 1, 2022</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>October 9, 2020</study_first_posted>
    <last_update_posted>February 2, 2022</last_update_posted>
    <locations>
      <location>USC/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States</location>
      <location>David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States</location>
      <location>University California, San Diego (CRS 4601), San Diego, California, United States</location>
      <location>Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States</location>
      <location>University of Florida (5051), Jacksonville, Florida, United States</location>
      <location>Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States</location>
      <location>Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States</location>
      <location>Ann &amp; Robert H Lurie Children's Hospital of Chicago (4001), Chicago, Illinois, United States</location>
      <location>Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States</location>
      <location>Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States</location>
      <location>Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States</location>
      <location>Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States</location>
      <location>Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States</location>
      <location>Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States</location>
      <location>St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States</location>
      <location>Texas Children's Hospital (Site 5128), Houston, Texas, United States</location>
      <location>IMPAACT/ Gamma Project/ UPR Pediatric HIV/AIDS Research CRS, San Juan, Puerto Rico</location>
      <location>University of Puerto Rico Pediatric HIV/AIDS CRS (6601), San Juan, Puerto Rico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04582266</url>
  </study>
  <study rank="21">
    <nct_id>NCT04723394</nct_id>
    <title>Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults</title>
    <acronym>TACKLE</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AZD7442</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>A composite of either severe COVID-19 or death from any cause through Day 29.</outcome_measure>
      <outcome_measure>AEs, SAEs, and AESIs through end of study.</outcome_measure>
      <outcome_measure>A composite of either death from any cause or hospitalization for COVID-19 complications or sequelae during the 168-day post-dose period (Day 1 to Day 169).</outcome_measure>
      <outcome_measure>The incidence of participants with respiratory failure, defined as requirement for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow nasal cannula oxygen delivery.</outcome_measure>
      <outcome_measure>COVID-19 symptom severity assessments based on symptom severity scores over time during the 28-day period from and including the day of the dose of AZD7442 or placebo.</outcome_measure>
      <outcome_measure>Progression through Day 29 of one or more COVID-19-associated symptoms to a worse status than recorded in the participant-reported symptom diary at study entry, prior to start of AZD7442 or placebo.</outcome_measure>
      <outcome_measure>Detection (detectable versus undetectable) from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.</outcome_measure>
      <outcome_measure>Level of SARS-CoV-2 RNA from nasal swabs through Day 29.</outcome_measure>
      <outcome_measure>Change from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.</outcome_measure>
      <outcome_measure>Time to return to usual (pre-COVID-19) health through Day 29.</outcome_measure>
      <outcome_measure>Duration of fever through Day 29 defined as the last day in the participant-reported symptom diary on which a temperature greater than 100°F (37.8° C) was recorded or a potentially antipyretic drug, such as acetaminophen or ibuprofen, was taken.</outcome_measure>
      <outcome_measure>Incidence of ADA to AZD7442 in serum over time.</outcome_measure>
      <outcome_measure>Pharmacokinetics - Serum Concentration</outcome_measure>
      <outcome_measure>Pharmacokinetics - Maximum Serum Concentration</outcome_measure>
      <outcome_measure>Pharmacokinetics - Time to Maximum Serum Concentration</outcome_measure>
      <outcome_measure>Pharmacokinetics - Area under the plasma concentration-time curve to the last measurable time point</outcome_measure>
      <outcome_measure>Pharmacokinetics - Area under the plasma concentration-time curve extrapolated to infinity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>910</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>D8851C00001</other_id>
    </other_ids>
    <start_date>January 28, 2021</start_date>
    <primary_completion_date>August 21, 2021</primary_completion_date>
    <completion_date>October 21, 2022</completion_date>
    <study_first_posted>January 25, 2021</study_first_posted>
    <last_update_posted>September 20, 2021</last_update_posted>
    <locations>
      <location>Research Site, Jasper, Alabama, United States</location>
      <location>Research Site, Tucson, Arizona, United States</location>
      <location>Research Site, Long Beach, California, United States</location>
      <location>Research Site, Northridge, California, United States</location>
      <location>Research Site, Cutler Bay, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Pompano Beach, Florida, United States</location>
      <location>Research Site, Chicago, Illinois, United States</location>
      <location>Research Site, Lake Charles, Louisiana, United States</location>
      <location>Research Site, Saint Louis, Missouri, United States</location>
      <location>Research Site, La Vista, Nebraska, United States</location>
      <location>Research Site, New York, New York, United States</location>
      <location>Research Site, Charlotte, North Carolina, United States</location>
      <location>Research Site, Charlotte, North Carolina, United States</location>
      <location>Research Site, Statesville, North Carolina, United States</location>
      <location>Research Site, Fargo, North Dakota, United States</location>
      <location>Research Site, Columbus, Ohio, United States</location>
      <location>Research Site, West Columbia, South Carolina, United States</location>
      <location>Research Site, Dallas, Texas, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, Humble, Texas, United States</location>
      <location>Research Site, Buenos Aires, Argentina</location>
      <location>Research Site, Buenos Aires, Argentina</location>
      <location>Research Site, Ciudad de Buenos Aires, Argentina</location>
      <location>Research Site, Munro, Argentina</location>
      <location>Research Site, Blumenau, Brazil</location>
      <location>Research Site, Porto Alegre, Brazil</location>
      <location>Research Site, Ribeirão Preto, Brazil</location>
      <location>Research Site, Sorocaba, Brazil</location>
      <location>Research Site, São Paulo, Brazil</location>
      <location>Research Site, Plovdiv, Bulgaria</location>
      <location>Research Site, Sofia, Bulgaria</location>
      <location>Research Site, Sofia, Bulgaria</location>
      <location>Research Site, Vratsa, Bulgaria</location>
      <location>Research Site, Bilina, Czechia</location>
      <location>Research Site, Hradec Kralove, Czechia</location>
      <location>Research Site, Kolin, Czechia</location>
      <location>Research Site, Ostrava, Czechia</location>
      <location>Research Site, Svitavy, Czechia</location>
      <location>Research Site, Berlin - Friedrichshain, Germany</location>
      <location>Research Site, Berlin, Germany</location>
      <location>Research Site, Berlin, Germany</location>
      <location>Research Site, Frankfurt/Main, Germany</location>
      <location>Research Site, Frankfurt, Germany</location>
      <location>Research Site, Hamburg, Germany</location>
      <location>Research Site, Hannover, Germany</location>
      <location>Research Site, Koblenz, Germany</location>
      <location>Research Site, Köln, Germany</location>
      <location>Research Site, Mainz, Germany</location>
      <location>Research Site, München-Pasing, Germany</location>
      <location>Research Site, München, Germany</location>
      <location>Research Site, Budapest, Hungary</location>
      <location>Research Site, Budapest, Hungary</location>
      <location>Research Site, Debrecen, Hungary</location>
      <location>Research Site, Gyöngyös, Hungary</location>
      <location>Research Site, Nyíregyháza, Hungary</location>
      <location>Research Site, Tatabánya, Hungary</location>
      <location>Research Site, Bologna, Italy</location>
      <location>Research Site, Guastalla, Italy</location>
      <location>Research Site, Milano, Italy</location>
      <location>Research Site, Milano, Italy</location>
      <location>Research Site, Napoli, Italy</location>
      <location>Research Site, Piacenza, Italy</location>
      <location>Research Site, Pisa, Italy</location>
      <location>Research Site, Roma, Italy</location>
      <location>Research Site, Chiba-shi, Japan</location>
      <location>Research Site, Hachioji-shi, Japan</location>
      <location>Research Site, Iruma-Gun, Japan</location>
      <location>Research Site, Kyoto-shi, Japan</location>
      <location>Research Site, Maebashi-shi, Japan</location>
      <location>Research Site, Narita-shi, Japan</location>
      <location>Research Site, Sendai-shi, Japan</location>
      <location>Research Site, Shinagawa-ku, Japan</location>
      <location>Research Site, Shinagawa-ku, Japan</location>
      <location>Research Site, Shinjuku-ku, Japan</location>
      <location>Research Site, Chihuahua, Mexico</location>
      <location>Research Site, Cuauhtemoc, Mexico</location>
      <location>Research Site, Cuautitlan Izcalli, Mexico</location>
      <location>Research Site, Ecatepec de Morelos, Mexico</location>
      <location>Research Site, Guadalajara, Mexico</location>
      <location>Research Site, Guadalajara, Mexico</location>
      <location>Research Site, Mazatlán, Mexico</location>
      <location>Research Site, Monterrey, Mexico</location>
      <location>Research Site, Mérida, Mexico</location>
      <location>Research Site, Tlalpan, Mexico</location>
      <location>Research Site, Tlalpan, Mexico</location>
      <location>Research Site, Lima, Peru</location>
      <location>Research Site, Rzeszów, Poland</location>
      <location>Research Site, Wołomin, Poland</location>
      <location>Research Site, Moscow, Russian Federation</location>
      <location>Research Site, Murmansk, Russian Federation</location>
      <location>Research Site, Saint-Petersburg, Russian Federation</location>
      <location>Research Site, Saint-Petersburg, Russian Federation</location>
      <location>Research Site, Saint-Petersburg, Russian Federation</location>
      <location>Research Site, Saint-Petersburg, Russian Federation</location>
      <location>Research Site, Saint-Petersburg, Russian Federation</location>
      <location>Research Site, Cabra, Spain</location>
      <location>Research Site, Centelles (Barcelona), Spain</location>
      <location>Research Site, Girona, Spain</location>
      <location>Research Site, Madrid, Spain</location>
      <location>Research Site, Málaga, Spain</location>
      <location>Research Site, Dnipro, Ukraine</location>
      <location>Research Site, Ivano-Frankivsk, Ukraine</location>
      <location>Research Site, Kherson, Ukraine</location>
      <location>Research Site, Blackpool, United Kingdom</location>
      <location>Research Site, Bracknell, United Kingdom</location>
      <location>Research Site, Bristol, United Kingdom</location>
      <location>Research Site, Cambridge, United Kingdom</location>
      <location>Research Site, Connor Downs, United Kingdom</location>
      <location>Research Site, Highgate, United Kingdom</location>
      <location>Research Site, Leicester, United Kingdom</location>
      <location>Research Site, Preston, United Kingdom</location>
      <location>Research Site, Rochdale, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04723394</url>
  </study>
  <study rank="22">
    <nct_id>NCT04540393</nct_id>
    <title>AZD1222 Vaccine for the Prevention of COVID-19</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AZD1222</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability].</outcome_measure>
      <outcome_measure>Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability].</outcome_measure>
      <outcome_measure>SARS-CoV-2 antigen-specific antibody levels</outcome_measure>
      <outcome_measure>The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen</outcome_measure>
      <outcome_measure>The rate of participants seroconverting from negative to positive SARS-CoV-2 N</outcome_measure>
      <outcome_measure>Quantity of SARS-CoV-2 neutralizing antibodies</outcome_measure>
      <outcome_measure>Count of peripheral blood mononuclear cells (PBMCs)</outcome_measure>
      <outcome_measure>Quantity of seasonal coronavirus antigens</outcome_measure>
      <outcome_measure>Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>Iqvia Pty Ltd</collaborator>
      <collaborator>Covance</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>130 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>D8111C00001</other_id>
    </other_ids>
    <start_date>September 2, 2020</start_date>
    <primary_completion_date>December 4, 2020</primary_completion_date>
    <completion_date>May 11, 2022</completion_date>
    <study_first_posted>September 7, 2020</study_first_posted>
    <last_update_posted>October 1, 2021</last_update_posted>
    <locations>
      <location>Research Site, Moscow, Russian Federation</location>
      <location>Research Site, Saint Petersburg, Russian Federation</location>
      <location>Research Site, Saint-Petersburg, Russian Federation</location>
      <location>Research Site, St. Petersburg, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04540393</url>
  </study>
  <study rank="23">
    <nct_id>NCT04351802</nct_id>
    <title>CORonavirus (COVID-19) Diagnostic Lung UltraSound Study</title>
    <acronym>COR-DLUS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Lung ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnosis of COVID-19 on lung ultrasound</outcome_measure>
      <outcome_measure>Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray</outcome_measure>
      <outcome_measure>Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray</outcome_measure>
      <outcome_measure>Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19</outcome_measure>
      <outcome_measure>Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Plymouth NHS Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>282661</other_id>
    </other_ids>
    <start_date>May 11, 2020</start_date>
    <primary_completion_date>February 15, 2021</primary_completion_date>
    <completion_date>February 15, 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>October 15, 2021</last_update_posted>
    <locations>
      <location>Derriford Hospital, Plymouth, Devon, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351802</url>
  </study>
  <study rank="24">
    <nct_id>NCT04883138</nct_id>
    <title>Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GIGA-2050</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of treatment-emergent adverse events (TEAEs)</outcome_measure>
      <outcome_measure>Incidence of dose limiting toxicities (DLTs)</outcome_measure>
      <outcome_measure>Change from baseline of vital signs, physical examination, and clinical laboratory assessments</outcome_measure>
      <outcome_measure>Incidence of infusion-related reactions (IRR) and hypersensitivity reactions</outcome_measure>
      <outcome_measure>Pharmacological evaluation of single doses of GIGA-2050</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GigaGen, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GG-GIGA-2050-001</other_id>
    </other_ids>
    <start_date>May 24, 2021</start_date>
    <primary_completion_date>January 11, 2022</primary_completion_date>
    <completion_date>January 11, 2022</completion_date>
    <study_first_posted>May 12, 2021</study_first_posted>
    <last_update_posted>January 26, 2022</last_update_posted>
    <locations>
      <location>Icahn School of Medicine at Mount Sinai, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04883138</url>
  </study>
  <study rank="25">
    <nct_id>NCT04359095</nct_id>
    <title>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Emtricitabine/tenofovir</intervention>
      <intervention type="Drug">Colchicine Pill</intervention>
      <intervention type="Drug">Rosuvastatin</intervention>
      <intervention type="Other">Standard treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection</outcome_measure>
      <outcome_measure>Time to death</outcome_measure>
      <outcome_measure>Number of Participants that are transferred to the Intensive Care Unit (ICU)</outcome_measure>
      <outcome_measure>Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.</outcome_measure>
      <outcome_measure>Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray</outcome_measure>
      <outcome_measure>Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad Nacional de Colombia</lead_sponsor>
      <collaborator>Pontificia Universidad Javeriana</collaborator>
      <collaborator>Clínica Colsanitas-Clínica Universitaria Colombia</collaborator>
      <collaborator>Hospital Universitario San Ignacio</collaborator>
      <collaborator>Hospital Universitario Nacional de Colombia (HUN)</collaborator>
      <collaborator>Fundación Cardioinfantil Instituto de Cardiología</collaborator>
      <collaborator>Clínica Infantil Santa María del Lago</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>650</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>76968</other_id>
    </other_ids>
    <start_date>August 18, 2020</start_date>
    <primary_completion_date>March 20, 2021</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>August 12, 2021</last_update_posted>
    <locations>
      <location>Clinica santa Maria del lago, Bogota, DC, Colombia</location>
      <location>Clínica Reina Sofía, Bogotá, Colombia</location>
      <location>Fundacion Cardio Infantil, Bogotá, Colombia</location>
      <location>Hospital Universitario San Ignacio, Bogotá, Colombia</location>
      <location>Clinica Universitaria Colombia, Bogotá, Colombia</location>
      <location>Hospital Universitario Nacional de Colombia, Bogotá, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359095</url>
  </study>
  <study rank="26">
    <nct_id>NCT05109546</nct_id>
    <title>Geriatric COVID-19 Serology</title>
    <acronym>SeroGerCov</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Retrospective study of COVID serologies in a geriatric population after infection or vaccination</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>76 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>8438</other_id>
    </other_ids>
    <start_date>October 15, 2021</start_date>
    <primary_completion_date>March 2022</primary_completion_date>
    <completion_date>March 31, 2022</completion_date>
    <study_first_posted>November 5, 2021</study_first_posted>
    <last_update_posted>November 17, 2021</last_update_posted>
    <locations>
      <location>Service SSR Gériatrique - Hôpitaux Universitaires de Strasbourg, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05109546</url>
  </study>
  <study rank="27">
    <nct_id>NCT05126498</nct_id>
    <title>Influence of the COVID-19 Pandemic on Dutch Surgical Patterns of Care</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">no intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of performed surgical procedures</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>30-day hospital readmissions (percentage)</outcome_measure>
      <outcome_measure>severe complications (Clavien-Dindo grade &gt; 3A)</outcome_measure>
      <outcome_measure>ICU admission (percentage)</outcome_measure>
      <outcome_measure>length of ICU stay (days)</outcome_measure>
      <outcome_measure>mortality rate (percentage)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Medical Center Groningen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40296</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>COVIDsurgII01</other_id>
    </other_ids>
    <start_date>August 1, 2020</start_date>
    <primary_completion_date>May 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>November 19, 2021</study_first_posted>
    <last_update_posted>November 19, 2021</last_update_posted>
    <locations>
      <location>UMCG, Groningen, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05126498</url>
  </study>
  <study rank="28">
    <nct_id>NCT04345445</nct_id>
    <title>Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Methylprednisolone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of patients requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Mean days of ventilation</outcome_measure>
      <outcome_measure>The proportion of patients requiring ICU admission</outcome_measure>
      <outcome_measure>Overall 28-day survival</outcome_measure>
      <outcome_measure>Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline</outcome_measure>
      <outcome_measure>Duration of hospital and ICU stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Malaya</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TVCS-COVID19</other_id>
    </other_ids>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>University Malaya Medical Centre, Kuala Lumpur, Malaysia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345445</url>
  </study>
  <study rank="29">
    <nct_id>NCT04508712</nct_id>
    <title>Long-term Outcomes in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Physical functions</outcome_measure>
      <outcome_measure>Respiratory function</outcome_measure>
      <outcome_measure>Cognitive function</outcome_measure>
      <outcome_measure>Depression status</outcome_measure>
      <outcome_measure>Sensory functions</outcome_measure>
      <outcome_measure>Heart function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>RenJi Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>COVID-19 Prognosis</other_id>
    </other_ids>
    <start_date>August 10, 2020</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>August 11, 2020</study_first_posted>
    <last_update_posted>October 23, 2020</last_update_posted>
    <locations>
      <location>Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04508712</url>
  </study>
  <study rank="30">
    <nct_id>NCT05195229</nct_id>
    <title>Quantifying Viral Load in Respiratory Particles That Are Generated by Children and Adults With COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">COVID-19 Aerosol Collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral Load in Aerosols generated from COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>2020P002886</other_id>
    </other_ids>
    <start_date>January 13, 2022</start_date>
    <primary_completion_date>March 1, 2022</primary_completion_date>
    <completion_date>May 1, 2022</completion_date>
    <study_first_posted>January 18, 2022</study_first_posted>
    <last_update_posted>January 18, 2022</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05195229</url>
  </study>
  <study rank="31">
    <nct_id>NCT04460547</nct_id>
    <title>Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Convalescent Plasma Transfusion</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">DAS181</intervention>
      <intervention type="Drug">Ivermectin</intervention>
      <intervention type="Drug">Interferon Beta-1A</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Geographical distribution of the interventional studies after 11th of March 2020.</outcome_measure>
      <outcome_measure>Geographical distribution of the Observational studies after 11th of March 2020.</outcome_measure>
      <outcome_measure>Monthly Research study completion rate as per geographic distribution of the Research.</outcome_measure>
      <outcome_measure>Statistical correlation of the interventional studies Research with developed, developing and under developed countries.</outcome_measure>
      <outcome_measure>Statistical correlation of the observational studies Research with developed, developing and under developed countries.</outcome_measure>
      <outcome_measure>Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.</outcome_measure>
      <outcome_measure>Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.</outcome_measure>
      <outcome_measure>Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Qassim University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>COAHS</other_id>
    </other_ids>
    <start_date>July 25, 2020</start_date>
    <primary_completion_date>August 15, 2020</primary_completion_date>
    <completion_date>September 20, 2020</completion_date>
    <study_first_posted>July 7, 2020</study_first_posted>
    <last_update_posted>July 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04460547</url>
  </study>
  <study rank="32">
    <nct_id>NCT04361422</nct_id>
    <title>Isotretinoin in Treatment of COVID-19</title>
    <acronym>Randomized</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Isotretinoin Only Product in Oral Dose Form</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical clearance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>9469305c</other_id>
    </other_ids>
    <start_date>December 1, 2020</start_date>
    <primary_completion_date>August 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>September 23, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361422</url>
  </study>
  <study rank="33">
    <nct_id>NCT04625972</nct_id>
    <title>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults</title>
    <acronym>STORM CHASER</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AZD7442</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness</outcome_measure>
      <outcome_measure>AEs, SAEs, MAAEs, and AESIs post dose of IMP</outcome_measure>
      <outcome_measure>The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP</outcome_measure>
      <outcome_measure>The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARSCoV- 2 nucleocapsid antibodies</outcome_measure>
      <outcome_measure>The incidence of COVID-19-related death occurring after dosing with IMP</outcome_measure>
      <outcome_measure>The incidence of all-cause mortality occurring after dosing with IMP</outcome_measure>
      <outcome_measure>Serum AZD7442 concentrations, PK parameters if data permit.</outcome_measure>
      <outcome_measure>Incidence of ADA to AZD7442 in serum</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>Iqvia Pty Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>D8850C00003</other_id>
    </other_ids>
    <start_date>December 2, 2020</start_date>
    <primary_completion_date>April 7, 2021</primary_completion_date>
    <completion_date>June 19, 2022</completion_date>
    <study_first_posted>November 12, 2020</study_first_posted>
    <last_update_posted>December 8, 2021</last_update_posted>
    <locations>
      <location>Research Site, Guntersville, Alabama, United States</location>
      <location>Research Site, Tempe, Arizona, United States</location>
      <location>Research Site, Little Rock, Arkansas, United States</location>
      <location>Research Site, Bakersfield, California, United States</location>
      <location>Research Site, Corona, California, United States</location>
      <location>Research Site, Garden Grove, California, United States</location>
      <location>Research Site, Huntington Beach, California, United States</location>
      <location>Research Site, Huntington Park, California, United States</location>
      <location>Research Site, Modesto, California, United States</location>
      <location>Research Site, Coral Springs, Florida, United States</location>
      <location>Research Site, Miami Lakes, Florida, United States</location>
      <location>Research Site, Miami Lakes, Florida, United States</location>
      <location>Research Site, Miami Springs, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Mount Dora, Florida, United States</location>
      <location>Research Site, North Miami, Florida, United States</location>
      <location>Research Site, Pembroke Pines, Florida, United States</location>
      <location>Research Site, Pompano Beach, Florida, United States</location>
      <location>Research Site, Tampa, Florida, United States</location>
      <location>Research Site, West Palm Beach, Florida, United States</location>
      <location>Research Site, Atlanta, Georgia, United States</location>
      <location>Research Site, Buford, Georgia, United States</location>
      <location>Research Site, Conyers, Georgia, United States</location>
      <location>Research Site, Chicago, Illinois, United States</location>
      <location>Research Site, Chicago, Illinois, United States</location>
      <location>Research Site, Hazel Crest, Illinois, United States</location>
      <location>Research Site, Noblesville, Indiana, United States</location>
      <location>Research Site, West Des Moines, Iowa, United States</location>
      <location>Research Site, Wichita, Kansas, United States</location>
      <location>Research Site, Owensboro, Kentucky, United States</location>
      <location>Research Site, Bethesda, Maryland, United States</location>
      <location>Research Site, High Point, North Carolina, United States</location>
      <location>Research Site, Wilmington, North Carolina, United States</location>
      <location>Research Site, Orangeburg, South Carolina, United States</location>
      <location>Research Site, Dallas, Texas, United States</location>
      <location>Research Site, El Paso, Texas, United States</location>
      <location>Research Site, Friendswood, Texas, United States</location>
      <location>Research Site, Gonzales, Texas, United States</location>
      <location>Research Site, Harlingen, Texas, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, San Antonio, Texas, United States</location>
      <location>Research Site, Riverton, Utah, United States</location>
      <location>Research Site, Alexandria, Virginia, United States</location>
      <location>Research Site, Portsmouth, Virginia, United States</location>
      <location>Research Site, Richmond, Virginia, United States</location>
      <location>Research Site, Tacoma, Washington, United States</location>
      <location>Research Site, Bournemouth, United Kingdom</location>
      <location>Research Site, Hayle, United Kingdom</location>
      <location>Research Site, London, United Kingdom</location>
      <location>Research Site, London, United Kingdom</location>
      <location>Research Site, London, United Kingdom</location>
      <location>Research Site, Manchester, United Kingdom</location>
      <location>Research Site, Southampton, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04625972</url>
  </study>
  <study rank="34">
    <nct_id>NCT04355741</nct_id>
    <title>Gut Microbiota, &quot;Spark and Flame&quot; of COVID-19 Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Exposure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.</outcome_measure>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients in relation to mortality.</outcome_measure>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.</outcome_measure>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidade Nova de Lisboa</lead_sponsor>
      <collaborator>NOVA Medical School of Universidade NOVA de Lisboa</collaborator>
      <collaborator>Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental</collaborator>
      <collaborator>Centro Hospitalar Universitário São João</collaborator>
      <collaborator>CUF Academic and Research Medical Center</collaborator>
      <collaborator>Hospital CUF Infante Santo, S.A.</collaborator>
      <collaborator>Centro de Medicina Laboratorial Germano de Sousa, S.A.</collaborator>
      <collaborator>CINTESIS - Center for Health Technology and Services Research</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>COVID19_Microbiota</other_id>
    </other_ids>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 16, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>August 25, 2020</last_update_posted>
    <locations>
      <location>Hospital CUF Infante Santo, S.A., Lisbon, Portugal</location>
      <location>Hospital de São Francisco Xavier, Lisbon, Portugal</location>
      <location>Centro Hospitalar Universitário São João, Oporto, Portugal</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355741</url>
  </study>
  <study rank="35">
    <nct_id>NCT04388683</nct_id>
    <title>Inhaled Nitric Oxide for Preventing Progression in COVID-19</title>
    <acronym>NO-COVID-19</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.</outcome_measure>
      <outcome_measure>Prevention of progression assessed by an alternate severity scale</outcome_measure>
      <outcome_measure>Time to reaching maximal severity score</outcome_measure>
      <outcome_measure>Proportion of patients in each stage at maximum severity</outcome_measure>
      <outcome_measure>PaO2/FIO2 or SaO2/FIO2 ratio, measured daily</outcome_measure>
      <outcome_measure>Length of hospital Stay (death assigned as worst case)</outcome_measure>
      <outcome_measure>Frequency of Intubation, ECMO, or need to intubate with &quot;Do Not Resuscitate&quot; order</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>IL6 level</outcome_measure>
      <outcome_measure>TNF-alpha level</outcome_measure>
      <outcome_measure>Fibrinogen level</outcome_measure>
      <outcome_measure>CRP level</outcome_measure>
      <outcome_measure>Ferritin Level</outcome_measure>
      <outcome_measure>D-dimer level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tufts Medical Center</lead_sponsor>
      <collaborator>Bellerophon</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY00000554</other_id>
    </other_ids>
    <start_date>May 12, 2020</start_date>
    <primary_completion_date>November 23, 2020</primary_completion_date>
    <completion_date>November 23, 2020</completion_date>
    <study_first_posted>May 14, 2020</study_first_posted>
    <last_update_posted>September 30, 2021</last_update_posted>
    <locations>
      <location>Tufts Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04388683</url>
  </study>
  <study rank="36">
    <nct_id>NCT04578158</nct_id>
    <title>Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Standard COVID-19 care</intervention>
      <intervention type="Dietary Supplement">Quercetin Phytosome</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with COVID-19 disease progression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Liaquat University of Medical &amp; Health Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LUMHS/REC/894</other_id>
    </other_ids>
    <start_date>September 29, 2020</start_date>
    <primary_completion_date>March 28, 2021</primary_completion_date>
    <completion_date>April 15, 2021</completion_date>
    <study_first_posted>October 8, 2020</study_first_posted>
    <last_update_posted>April 22, 2021</last_update_posted>
    <locations>
      <location>Liaquat University Hospital, Jāmshoro, Sindh, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04578158</url>
  </study>
  <study rank="37">
    <nct_id>NCT04377763</nct_id>
    <title>Developement and Evaluation of Serological Assays for COVID-19</title>
    <acronym>SEROCOV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Sensibility and specificity</outcome_measure>
      <outcome_measure>Delay between the first symptoms and the positive serological result</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>20MWI-SEROCOV</other_id>
    </other_ids>
    <start_date>July 15, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>May 6, 2020</study_first_posted>
    <last_update_posted>February 25, 2021</last_update_posted>
    <locations>
      <location>Laboratory of microbiology of hospital hygiene, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04377763</url>
  </study>
  <study rank="38">
    <nct_id>NCT04932941</nct_id>
    <title>MP1032 Treatment in Patients With Moderate to Severe COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP1032</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants with Disease Progression at Day 14</outcome_measure>
      <outcome_measure>Percentage of Participants with Disease Progression at Day 28</outcome_measure>
      <outcome_measure>Percentage of Participants with Disease Resolution at Day 28</outcome_measure>
      <outcome_measure>All-cause Mortality Rate at Day 28</outcome_measure>
      <outcome_measure>Change from Baseline in Clinical Status related to COVID-19 according to the NIAID 8-point Ordinal Scale at Day 28</outcome_measure>
      <outcome_measure>Percentage of Participants with Disease Resolution at Day 14</outcome_measure>
      <outcome_measure>All-cause Mortality Rate at Day 14 and Day 60</outcome_measure>
      <outcome_measure>Change from Baseline in Clinical Status related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 14</outcome_measure>
      <outcome_measure>Percentage of Participants requiring Invasive Ventilation (Mechanical Ventilator and/or ECMO), or who are not Alive on Day 14 and Day 28</outcome_measure>
      <outcome_measure>Percentage of Participants in each category of the NIAID 8-point Ordinal Scale</outcome_measure>
      <outcome_measure>Time to (First) Improvement of at least 1 Category on the NIAID 8-point Ordinal Scale</outcome_measure>
      <outcome_measure>The Odds Ratio for the Number of Participants with Clinical Status Improvement From Baseline on the NIAID 8-point Ordinal Scale at Day 14 and Day 28</outcome_measure>
      <outcome_measure>Total Duration of Hospitalization at Day 28 and Day 60</outcome_measure>
      <outcome_measure>Percentage of Participants alive and testing negative for COVID-19 at Day 14, Day 28, and Day 60</outcome_measure>
      <outcome_measure>Number of Participants with treatment emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Participants with Vital Sign Abnormalities</outcome_measure>
      <outcome_measure>Number of Participants With Physical Examination Findings</outcome_measure>
      <outcome_measure>Number of Participants with Laboratory Findings</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of MP1032</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time curve from Time Zero (pre-dose) to last non-zero concentration (AUC0-t) of MP1032</outcome_measure>
      <outcome_measure>Apparent Elimination Rate Constant (K) of MP1032</outcome_measure>
      <outcome_measure>Apparent Body Clearance (CL) of MP1032</outcome_measure>
      <outcome_measure>Apparent Volume of Distribution (Vd) of MP1032</outcome_measure>
      <outcome_measure>Plasma Concentration Prior to the Next Dose (Ctrough) of MP1032</outcome_measure>
      <outcome_measure>Average Observed Plasma Concentration at Steady State of MP1032</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>MetrioPharm AG</lead_sponsor>
      <collaborator>Syneos Health, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MP1032-CT05</other_id>
      <other_id>2021-000344-21</other_id>
    </other_ids>
    <start_date>October 19, 2021</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>June 21, 2021</study_first_posted>
    <last_update_posted>February 2, 2022</last_update_posted>
    <locations>
      <location>Snake River Research PLLC, Idaho Falls, Idaho, United States</location>
      <location>Richmond University Medical Center, Staten Island, New York, United States</location>
      <location>MHAT Dr. Stamen Iliev AD, Montana, Bulgaria</location>
      <location>SHATPD Pernik EOOD, Pernik, Bulgaria</location>
      <location>&quot;Second Multiprofile Hospital For Active Treatment - Sofia&quot; Ead, Sofia, Bulgaria</location>
      <location>Umhatem&quot;N.I.Pirogov&quot;, Sofia, Bulgaria</location>
      <location>SHATPPD Sata Zagora EOOD, Stara Zagora, Bulgaria</location>
      <location>Centre Hospitalier Victor Dupouy, Argenteuil, France</location>
      <location>CHU de Grenoble Alpes, Grenoble Cedex 9, France</location>
      <location>Centre Hospitalier Lyon Sud, Pierre-Benite CEDEX, France</location>
      <location>DE KK Infektológiai Klinika, Debrecen, Hungary</location>
      <location>Flor Ferenc Hospital of Pest County, Kistarcsa, Hungary</location>
      <location>IRCCS Ospedale San Raffaele, Milan, Italy</location>
      <location>Polo Universitario - L'Azienda Ospedaliera Luigi Sacco, Milan, Italy</location>
      <location>Policlinico Agostino Gemelli, Roma, Italy</location>
      <location>Spitalul Clinic de Boli Infectioase si Tropicale &quot;Dr. Victor Babes&quot;, Bucharest, Romania</location>
      <location>Spitalul Municipal Caracal, Caracal, Romania</location>
      <location>Spitalul Clinic de Boli Infectioase &quot;Sfanta Parascheva&quot;, Iaşi, Romania</location>
      <location>Spitalul Judetean de Urgenta &quot;Sfantul Ioan cel Nou&quot;, Suceava, Romania</location>
      <location>Clinica Anestezie si Terapie Intensiva, Timişoara, Romania</location>
      <location>Hospital Clinic de Barcelona Hospital Clinic i Provincial, Barcelona, Spain</location>
      <location>Hospital Ramon y Cajal, Edificio Central, Madrid, Spain</location>
      <location>Hospital Clínico Universitario de Salamanca, Salamanca, Spain</location>
      <location>Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain</location>
      <location>Hospital Universitario de Valme, Sevilla, Spain</location>
      <location>Hospital Álvaro Cunqueiro, Vigo, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04932941</url>
  </study>
  <study rank="39">
    <nct_id>NCT04421534</nct_id>
    <title>Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lactoferrin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Rate of virological cure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CUKA-001</other_id>
    </other_ids>
    <start_date>June 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>June 9, 2020</study_first_posted>
    <last_update_posted>June 9, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04421534</url>
  </study>
  <study rank="40">
    <nct_id>NCT04501796</nct_id>
    <title>A Trial of NT-I7 in COVID-19 (SPESELPIS)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Double-Blind NT-I7</intervention>
      <intervention type="Drug">Double-Blind Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion</outcome_measure>
      <outcome_measure>Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NeoImmuneTech</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>University of Nebraska</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIT-116 (SPESELPIS)</other_id>
    </other_ids>
    <start_date>November 27, 2020</start_date>
    <primary_completion_date>March 2022</primary_completion_date>
    <completion_date>June 2022</completion_date>
    <study_first_posted>August 6, 2020</study_first_posted>
    <last_update_posted>December 13, 2021</last_update_posted>
    <locations>
      <location>Nih/Niaid, Bethesda, Maryland, United States</location>
      <location>University of Nebraska Medical Center, Omaha, Nebraska, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04501796</url>
  </study>
  <study rank="41">
    <nct_id>NCT04428801</nct_id>
    <title>Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">autologous adipose-derived stem cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication</outcome_measure>
      <outcome_measure>The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group</outcome_measure>
      <outcome_measure>COVID-19 incidence rates in both the study and control groups</outcome_measure>
      <outcome_measure>The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.</outcome_measure>
      <outcome_measure>The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.</outcome_measure>
      <outcome_measure>Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.</outcome_measure>
      <outcome_measure>Change of lymphocyte count in white blood cell counts from the baseline</outcome_measure>
      <outcome_measure>Change of PaO2 arterial blood gases from the baseline</outcome_measure>
      <outcome_measure>Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups</outcome_measure>
      <outcome_measure>COVID-19 mortality rates for both study and control groups</outcome_measure>
      <outcome_measure>Change of C-reactive protein (CRP) (mg/L) from the baseline</outcome_measure>
      <outcome_measure>Change of D-dimer (mg/L) from the baseline</outcome_measure>
      <outcome_measure>Change of Procalcitonin (ug)/L from the baseline</outcome_measure>
      <outcome_measure>Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline</outcome_measure>
      <outcome_measure>Change of Bilirubin (mg/dL) from the baseline</outcome_measure>
      <outcome_measure>Change of Creatinine (mg/dL) from the baseline</outcome_measure>
      <outcome_measure>Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline</outcome_measure>
      <outcome_measure>The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group</outcome_measure>
      <outcome_measure>Quantifying viral RNA in stool for baseline and final follow-up.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Celltex Therapeutics Corporation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTX0020-003</other_id>
    </other_ids>
    <start_date>September 2021</start_date>
    <primary_completion_date>September 2022</primary_completion_date>
    <completion_date>September 2024</completion_date>
    <study_first_posted>June 11, 2020</study_first_posted>
    <last_update_posted>July 23, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04428801</url>
  </study>
  <study rank="42">
    <nct_id>NCT04625725</nct_id>
    <title>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.</title>
    <acronym>PROVENT</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AZD7442</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness</outcome_measure>
      <outcome_measure>AEs, SAEs, MAAEs, and AESIs post dose of IMP</outcome_measure>
      <outcome_measure>The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 nucleocapsid antibodies.</outcome_measure>
      <outcome_measure>The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP</outcome_measure>
      <outcome_measure>The incidence of COVID-19-related Emergency Department visits occurring after dosing with IMP</outcome_measure>
      <outcome_measure>Serum AZD7442 concentrations, PK parameters if data permit.</outcome_measure>
      <outcome_measure>Incidence of ADA to AZD7442 in serum.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>Iqvia Pty Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>5197</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>D8850C00002</other_id>
    </other_ids>
    <start_date>November 21, 2020</start_date>
    <primary_completion_date>May 5, 2021</primary_completion_date>
    <completion_date>November 30, 2023</completion_date>
    <study_first_posted>November 12, 2020</study_first_posted>
    <last_update_posted>February 3, 2022</last_update_posted>
    <locations>
      <location>Research Site, Birmingham, Alabama, United States</location>
      <location>Research Site, Tempe, Arizona, United States</location>
      <location>Research Site, Little Rock, Arkansas, United States</location>
      <location>Research Site, Cerritos, California, United States</location>
      <location>Research Site, Fresno, California, United States</location>
      <location>Research Site, Garden Grove, California, United States</location>
      <location>Research Site, Huntington Beach, California, United States</location>
      <location>Research Site, Lancaster, California, United States</location>
      <location>Research Site, Modesto, California, United States</location>
      <location>Research Site, Victorville, California, United States</location>
      <location>Research Site, Westminster, California, United States</location>
      <location>Research Site, Hartford, Connecticut, United States</location>
      <location>Research Site, Middlebury, Connecticut, United States</location>
      <location>Research Site, Clearwater, Florida, United States</location>
      <location>Research Site, Coral Springs, Florida, United States</location>
      <location>Research Site, Hollywood, Florida, United States</location>
      <location>Research Site, Lauderdale Lakes, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Ormond Beach, Florida, United States</location>
      <location>Research Site, Pompano Beach, Florida, United States</location>
      <location>Research Site, Wesley Chapel, Florida, United States</location>
      <location>Research Site, West Palm Beach, Florida, United States</location>
      <location>Research Site, Atlanta, Georgia, United States</location>
      <location>Research Site, Columbus, Georgia, United States</location>
      <location>Research Site, Conyers, Georgia, United States</location>
      <location>Research Site, Chicago, Illinois, United States</location>
      <location>Research Site, Hazel Crest, Illinois, United States</location>
      <location>Research Site, Quincy, Illinois, United States</location>
      <location>Research Site, Evansville, Indiana, United States</location>
      <location>Research Site, Noblesville, Indiana, United States</location>
      <location>Research Site, Wichita, Kansas, United States</location>
      <location>Research Site, Wichita, Kansas, United States</location>
      <location>Research Site, Minneapolis, Minnesota, United States</location>
      <location>Research Site, Minneapolis, Minnesota, United States</location>
      <location>Research Site, Saint Louis, Missouri, United States</location>
      <location>Research Site, Omaha, Nebraska, United States</location>
      <location>Research Site, Las Vegas, Nevada, United States</location>
      <location>Research Site, Albuquerque, New Mexico, United States</location>
      <location>Research Site, Bronx, New York, United States</location>
      <location>Research Site, Jamaica, New York, United States</location>
      <location>Research Site, Ridgewood, New York, United States</location>
      <location>Research Site, Greensboro, North Carolina, United States</location>
      <location>Research Site, Columbus, Ohio, United States</location>
      <location>Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Research Site, Summerville, South Carolina, United States</location>
      <location>Research Site, Rapid City, South Dakota, United States</location>
      <location>Research Site, Austin, Texas, United States</location>
      <location>Research Site, El Paso, Texas, United States</location>
      <location>Research Site, El Paso, Texas, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, San Antonio, Texas, United States</location>
      <location>Research Site, San Antonio, Texas, United States</location>
      <location>Research Site, Shenandoah, Texas, United States</location>
      <location>Research Site, Sugar Land, Texas, United States</location>
      <location>Research Site, Layton, Utah, United States</location>
      <location>Research Site, Alexandria, Virginia, United States</location>
      <location>Research Site, Chesapeake, Virginia, United States</location>
      <location>Research Site, Alken, Belgium</location>
      <location>Research Site, Bruxelles, Belgium</location>
      <location>Research Site, Gozée, Belgium</location>
      <location>Research Site, Namur, Belgium</location>
      <location>Research Site, Wetteren, Belgium</location>
      <location>Research Site, Clermont-Ferrand cedex, France</location>
      <location>Research Site, Dijon cedex, France</location>
      <location>Research Site, La Roche S/ Yon Cedex 9, France</location>
      <location>Research Site, Lille, France</location>
      <location>Research Site, Limoges cedex, France</location>
      <location>Research Site, Nantes Cedex 1, France</location>
      <location>Research Site, Paris cedex 10, France</location>
      <location>Research Site, Paris cedex 14, France</location>
      <location>Research Site, Saint Etienne Cedex 2, France</location>
      <location>Research Site, Tours cedex 9, France</location>
      <location>Research Site, Barcelona, Spain</location>
      <location>Research Site, Madrid, Spain</location>
      <location>Research Site, Madrid, Spain</location>
      <location>Research Site, Marbella (Málaga), Spain</location>
      <location>Research Site, Pozuelo de Alarcón, Spain</location>
      <location>Research Site, Bournemouth, United Kingdom</location>
      <location>Research Site, Enfield, United Kingdom</location>
      <location>Research Site, Hayle, United Kingdom</location>
      <location>Research Site, London, United Kingdom</location>
      <location>Research Site, Preston, United Kingdom</location>
      <location>Research Site, Rochdale, United Kingdom</location>
      <location>Research Site, Salford, United Kingdom</location>
      <location>Research Site, Torpoint, United Kingdom</location>
      <location>Research Site, Wakefield, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04625725</url>
  </study>
  <study rank="43">
    <nct_id>NCT04466644</nct_id>
    <title>COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">ELISA</intervention>
      <intervention type="Diagnostic Test">RT-PCR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs</outcome_measure>
      <outcome_measure>Ratio of asymptomatic immunized (IgG) population</outcome_measure>
      <outcome_measure>To validate saliva specimens as a biological sample for COVID-19 testing</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Igenomix</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGX2-COV-JC-20-04</other_id>
      <other_id>20201490</other_id>
    </other_ids>
    <start_date>June 8, 2020</start_date>
    <primary_completion_date>August 24, 2020</primary_completion_date>
    <completion_date>August 25, 2020</completion_date>
    <study_first_posted>July 10, 2020</study_first_posted>
    <last_update_posted>September 14, 2020</last_update_posted>
    <locations>
      <location>Boston IVF Fertility Clinic, Boston, Massachusetts, United States</location>
      <location>Utah Fertility Clinic, Pleasant Grove, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04466644</url>
  </study>
  <study rank="44">
    <nct_id>NCT04343183</nct_id>
    <title>Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Hyperbaric Oxygen Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Decrease incidence of intubation by 30% or greater</outcome_measure>
      <outcome_measure>Decrease renal injury</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ochsner Health System</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY00001051</other_id>
    </other_ids>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Ochsner Medical Center, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343183</url>
  </study>
  <study rank="45">
    <nct_id>NCT04347915</nct_id>
    <title>The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clevudine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)</outcome_measure>
      <outcome_measure>The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests</outcome_measure>
      <outcome_measure>The rate of subjects indicated by the improvement of lung invasive</outcome_measure>
      <outcome_measure>The change of viral load</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bukwang Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BK-CLV-201</other_id>
    </other_ids>
    <start_date>May 6, 2020</start_date>
    <primary_completion_date>January 30, 2021</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>January 27, 2021</last_update_posted>
    <locations>
      <location>Korea University Guro Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347915</url>
  </study>
  <study rank="46">
    <nct_id>NCT04470622</nct_id>
    <title>Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aprepitant injectable emulsion</intervention>
      <intervention type="Drug">Saline Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of subjects alive and discharged from the hospital.</outcome_measure>
      <outcome_measure>Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).</outcome_measure>
      <outcome_measure>Time to discharge from hospital.</outcome_measure>
      <outcome_measure>Change from Baseline in Interleukin 6 (IL-6).</outcome_measure>
      <outcome_measure>Incidence of treatment-emergent adverse events.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Heron Therapeutics</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HTX-019-202</other_id>
    </other_ids>
    <start_date>July 20, 2020</start_date>
    <primary_completion_date>April 9, 2021</primary_completion_date>
    <completion_date>June 3, 2021</completion_date>
    <study_first_posted>July 14, 2020</study_first_posted>
    <last_update_posted>October 20, 2021</last_update_posted>
    <locations>
      <location>Helen Keller Hospital, Sheffield, Alabama, United States</location>
      <location>University of California, Irvine Medical Center, Orange, California, United States</location>
      <location>Yale University School of Medicine, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04470622</url>
  </study>
  <study rank="47">
    <nct_id>NCT04610554</nct_id>
    <title>Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Lung diffusing capacity for nitric oxide (DLNO)</outcome_measure>
      <outcome_measure>Lung diffusing capacity for carbon monoxide (DLco)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>SARS-CoV-2_DLNO</other_id>
    </other_ids>
    <start_date>May 14, 2020</start_date>
    <primary_completion_date>October 12, 2020</primary_completion_date>
    <completion_date>October 12, 2020</completion_date>
    <study_first_posted>October 30, 2020</study_first_posted>
    <last_update_posted>October 30, 2020</last_update_posted>
    <locations>
      <location>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04610554</url>
  </study>
  <study rank="48">
    <nct_id>NCT04889040</nct_id>
    <title>Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19</title>
    <acronym>MORNINGSKY</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO7496998</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 hours)</outcome_measure>
      <outcome_measure>Time to Alleviation or Improvement of COVID-19 Symptoms (43 hours)</outcome_measure>
      <outcome_measure>Time to Alleviation of COVID-19 Symptoms (21.5 hours)</outcome_measure>
      <outcome_measure>Time to Alleviation of COVID-19 Symptoms (43 hours)</outcome_measure>
      <outcome_measure>Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms</outcome_measure>
      <outcome_measure>Time to Alleviation of Individual Symptoms</outcome_measure>
      <outcome_measure>Proportion of Participants Requiring Hospitalization for COVID-19</outcome_measure>
      <outcome_measure>Proportion of Participants with Greater than or Equal to 1 COVID-19 Related Medically Attended Visit</outcome_measure>
      <outcome_measure>Duration of Fever</outcome_measure>
      <outcome_measure>Frequency of COVID-19 Related Complications</outcome_measure>
      <outcome_measure>Proportion of Participants with any Post-Treatment Infection</outcome_measure>
      <outcome_measure>Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA</outcome_measure>
      <outcome_measure>Time to Cessation of SARS-CoV-2 Viral Shedding</outcome_measure>
      <outcome_measure>Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints</outcome_measure>
      <outcome_measure>Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Plasma Concentration of AT-511, AT-551, AT-229 and AT-273 at Specified Timepoints</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Atea Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1386</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CV43043</other_id>
      <other_id>2020-005759-18</other_id>
    </other_ids>
    <start_date>April 28, 2021</start_date>
    <primary_completion_date>November 17, 2021</primary_completion_date>
    <completion_date>November 17, 2021</completion_date>
    <study_first_posted>May 17, 2021</study_first_posted>
    <last_update_posted>February 4, 2022</last_update_posted>
    <locations>
      <location>Instituto Medico Rio Cuarto, Cordoba, Argentina</location>
      <location>Instituto Ave Pulmo, Mar Del Plata, Argentina</location>
      <location>Clínica Independencia, Munro, Argentina</location>
      <location>Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina</location>
      <location>Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán, Argentina</location>
      <location>Sanatorio Medico de Diagnostico Y Tratamiento, Santa Fe, Argentina</location>
      <location>Maison Médicale La Brèche, Châtelineau, Belgium</location>
      <location>Private Practice Dr Jean Benoit Martinot, Erpent, Belgium</location>
      <location>Medif, Gozée, Belgium</location>
      <location>L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil</location>
      <location>Chronos Pesquisa Clinica, Taguatinga, DF, Brazil</location>
      <location>Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil</location>
      <location>Hospital Agamenon Magalhães, Recife, PE, Brazil</location>
      <location>Hospital Nossa Senhora das Graças, Curitiba, PR, Brazil</location>
      <location>Hospital Erasto Gaertner, Curitiba, PR, Brazil</location>
      <location>Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil</location>
      <location>Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, Sao Jose Do Rio Preto, SP, Brazil</location>
      <location>CPQuali Pesquisa Clínica Sao Paulo, Sao Paulo, SP, Brazil</location>
      <location>Institute of Infectious Diseases Emilio Ribas, Sao Paulo, SP, Brazil</location>
      <location>Conjunto Hospitalar do Mandaqui, Sao Paulo, SP, Brazil</location>
      <location>Healthy Medical Center SAS, Zipaquirá, Colombia</location>
      <location>Aalborg Universitetshospital, Aalborg, Denmark</location>
      <location>Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark</location>
      <location>Sjællands Universitetshospital, Roskilde, Roskilde, Denmark</location>
      <location>Centre Hospitalier Victor Dupouy, Argenteuil, France</location>
      <location>Hôpital Saint Joseph, Marseille, France</location>
      <location>Hopital Tenon, Paris, France</location>
      <location>Klinikum Chemnitz gGmbH, Chemnitz, Germany</location>
      <location>Universitätsklinikum Frankfurt, Frankfurt, Germany</location>
      <location>Universitätsklinikum Freiburg, Freiburg, Germany</location>
      <location>Praxis am Ebertplatz, Köln, Germany</location>
      <location>ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco, Lecco, Lombardia, Italy</location>
      <location>Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy</location>
      <location>Comprensorio Amedeo Di Savoia Birago Di Vische, Torino, Piemonte, Italy</location>
      <location>Funabashi Central Hospital, Funabashi-Shi, Japan</location>
      <location>Higashiosaka city Medical Center, Higashiosaka-Shi, Japan</location>
      <location>Rinku General Medical Center, Izumisano, Japan</location>
      <location>Sagamihara Kyodo Hospital, Kanagawa, Japan</location>
      <location>Misyuku hospital, Meguro-Ku, Japan</location>
      <location>Nagoya City East Medical Center, Nagoya-Shi Chikusa-Ku, Japan</location>
      <location>Fujita Health University Banbuntane Hotokukai Hospital, Nagoya-shi, Japan</location>
      <location>Tokyo Metropolitan Police Hospital, Nakano-Ku, Japan</location>
      <location>IUHW Narita Hospital, Narita, Japan</location>
      <location>Houjin Syadan Kouhoukai Takagi Hospital, Okawa-Shi, Japan</location>
      <location>Okayama City Hospital, Okayama, Japan</location>
      <location>Ome Municipal General Hospital, Ome-Shi, Japan</location>
      <location>Osaka City General Hospital, Osaka, Japan</location>
      <location>National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Japan</location>
      <location>Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa, Japan</location>
      <location>St. Luke's International Hospital, Tokyo, Japan</location>
      <location>Edogawa Medicare Hospital, Tokyo, Japan</location>
      <location>Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan</location>
      <location>JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan</location>
      <location>Tokyo Medical University Hachioji Medical Center, Tokyo, Japan</location>
      <location>National Hospital Organization Kasumigaura Medical Center, Tsuchiurat, Japan</location>
      <location>Mie Prefectural Medical Centre, Yokkaichi, Japan</location>
      <location>CIMAB SA de CV, Torreón, Coahuila, Mexico</location>
      <location>Panamerican Clinical Research S.A de C.V., Guadalajara, Jalisco, Mexico</location>
      <location>Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), Mexico</location>
      <location>PanAmerican Clinical Research, Querétaro, Queréaro, Queretaro, Mexico</location>
      <location>Instituto Jalisciense de Investigacion Clinica S.A. de C.V., Guadalajara, Mexico</location>
      <location>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico</location>
      <location>CEPREP; Hospital Universitario, Monterrey, Mexico</location>
      <location>Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães, Portugal</location>
      <location>Centro Hospitalar de Leiria (CHL), Leiria, Portugal</location>
      <location>Unidade Local de Saude de Matosinhos SA, Matosinhos, Portugal</location>
      <location>Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucuresti, Romania</location>
      <location>County Hospital Caracal, Caracal, Romania</location>
      <location>Sibiu Emergency Clinical County Hospital, Sibiu, Romania</location>
      <location>Dr. Victor Babes Clinical Hospital of Pneumophthisiology and Infectious Diseases, Timişoara, Romania</location>
      <location>Dr JM Engelbrecht Trial site, Cape Town, South Africa</location>
      <location>TASK Eden, George, South Africa</location>
      <location>Langeberg Clinical Trials, Kraaifontein, South Africa</location>
      <location>Clinical Projects Research, Worcester, South Africa</location>
      <location>Hôpital Universitaire de Genève (HUG), Genève, Switzerland</location>
      <location>Universitätsspital Zürich, Zürich, Switzerland</location>
      <location>Gazi Universitesi Tip Fakultesi, Ankara, Turkey</location>
      <location>Hacettepe University Medical Faculty, Ankara, Turkey</location>
      <location>Koc University Medical Faculty Hospital, Istanbul, Turkey</location>
      <location>Ege University Medical Faculty, Izmir, Turkey</location>
      <location>Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey</location>
      <location>Ankara University Medical Faculty - PPDS, Çankaya, Turkey</location>
      <location>Istanbul University Cerrahpasa Medical Faculty Hospital; Tesvikiye Caddesi No:20, Şi̇şli̇, Turkey</location>
      <location>Municipal Non-profit enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Katerynoslav Governorate, Ukraine</location>
      <location>Municipal Non-profit Enterprise &quot;City Clinical Hospital #13&quot; of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine</location>
      <location>Public Non-Profit Enterprise &quot;City Outpatient Clinic #9&quot; of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine</location>
      <location>CNPE City Clinical Hospital #6 of DCC, Dnipro, Kholm Governorate, Ukraine</location>
      <location>Municipal Non-profit Enterprise &quot;City Clinical Hospital # 4&quot; of Dnipro City Council, Dnipro, KIEV Governorate, Ukraine</location>
      <location>CNPE Ivano-Frankivsk Regional Centre of Phthisiology and Pulmonology of IFRC, Ivano Frankivsk, KIEV Governorate, Ukraine</location>
      <location>Private Enterprise Private Manufacture Company &quot;Acinus&quot;, diagnostic and treatment center, Kirovograd, KIEV Governorate, Ukraine</location>
      <location>Medical Center LLC &quot;Harmony of Beauty&quot;, Kyiv, KIEV Governorate, Ukraine</location>
      <location>CNE Kyiv City Clinical Hospital#1 of Exec. Body, Kyiv, KIEV Governorate, Ukraine</location>
      <location>Medical Center of LLC Preventclinic, Kyiv, KIEV Governorate, Ukraine</location>
      <location>Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine</location>
      <location>Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem, Kyiv, KIEV Governorate, Ukraine</location>
      <location>Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsya, Podolia Governorate, Ukraine</location>
      <location>Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council, Zaporizhzhia, Tavria Okruha, Ukraine</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04889040</url>
  </study>
  <study rank="49">
    <nct_id>NCT04331509</nct_id>
    <title>COVID-19 Symptom Tracker</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physical health symptoms</outcome_measure>
      <outcome_measure>Lack of physical health symptoms</outcome_measure>
      <outcome_measure>Fever</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
      <collaborator>Zoe Global Limited</collaborator>
      <collaborator>Massachusetts General Hospital</collaborator>
      <collaborator>Harvard School of Public Health (HSPH)</collaborator>
      <collaborator>Stanford University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>COVID-19 Symptom tracker</other_id>
    </other_ids>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>March 23, 2022</primary_completion_date>
    <completion_date>March 23, 2022</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>King's College London, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331509</url>
  </study>
  <study rank="50">
    <nct_id>NCT04742569</nct_id>
    <title>Wearable Diagnostic for Detection of COVID-19 Infection</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.</outcome_measure>
      <outcome_measure>The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.</outcome_measure>
      <outcome_measure>The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.</outcome_measure>
      <outcome_measure>The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ClinOne, Inc.</lead_sponsor>
      <collaborator>BioIntelliSense, Inc</collaborator>
      <collaborator>Phillips North America, LLC</collaborator>
      <collaborator>University of Colorado, Denver</collaborator>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>790</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1294415</other_id>
    </other_ids>
    <start_date>December 21, 2020</start_date>
    <primary_completion_date>January 15, 2022</primary_completion_date>
    <completion_date>January 15, 2022</completion_date>
    <study_first_posted>February 8, 2021</study_first_posted>
    <last_update_posted>January 20, 2022</last_update_posted>
    <locations>
      <location>ClinOne, Inc, Greenwood Village, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04742569</url>
  </study>
  <study rank="51">
    <nct_id>NCT05197153</nct_id>
    <title>A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Vaccine</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Half dose of MVC-COV1901</intervention>
      <intervention type="Biological">Full dose of MVC-COV1901</intervention>
      <intervention type="Biological">AZD1222</intervention>
      <intervention type="Biological">Half dose of mRNA-1273</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Adverse Events from Day 1 to 28</outcome_measure>
      <outcome_measure>Primary Immunogenicity-1</outcome_measure>
      <outcome_measure>Primary Immunogenicity-2</outcome_measure>
      <outcome_measure>Primary Immunogenicity-3</outcome_measure>
      <outcome_measure>Primary Immunogenicity-4</outcome_measure>
      <outcome_measure>Incidence of Adverse Events from Day 1 to 181</outcome_measure>
      <outcome_measure>Secondary Immunogenicity (Humoral)-1</outcome_measure>
      <outcome_measure>Secondary Immunogenicity (Humoral)-2</outcome_measure>
      <outcome_measure>Secondary Immunogenicity (Humoral)-3</outcome_measure>
      <outcome_measure>Secondary Immunogenicity (Cellular)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medigen Vaccine Biologics Corp.</lead_sponsor>
      <collaborator>Coalition for Epidemic Preparedness Innovations</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>960</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>CT-COV-24</other_id>
    </other_ids>
    <start_date>January 2022</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>January 19, 2022</study_first_posted>
    <last_update_posted>January 19, 2022</last_update_posted>
    <locations>
      <location>Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan</location>
      <location>National Taiwan University Hospital, Taipei, Taiwan</location>
      <location>Taipei Municipal Wan Fang Hospital, Taipei, Taiwan</location>
      <location>Taipei Veteran General Hospital, Taipei, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05197153</url>
  </study>
  <study rank="52">
    <nct_id>NCT04523090</nct_id>
    <title>Catalysing the Containment of COVID-19</title>
    <acronym>C3-RCT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time specific disease severity</outcome_measure>
      <outcome_measure>Progression to severe disease</outcome_measure>
      <outcome_measure>Need for respiratory support (high flow nasal oxygen, non-invasive ventilation, or intubation) in those admitted to hospital because of disease progression.</outcome_measure>
      <outcome_measure>In-hospital and 30- and 60-day all-cause mortality.</outcome_measure>
      <outcome_measure>Time-specific viral load as measured by RT-PCR using NP swabs and sputum (where available).</outcome_measure>
      <outcome_measure>Cough aerosol sampling positivity</outcome_measure>
      <outcome_measure>Duration and severity of symptoms.</outcome_measure>
      <outcome_measure>Time-specific antibody titres (IgG and IgM).</outcome_measure>
      <outcome_measure>COVID-19 incidence rates in contacts.</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Cape Town</lead_sponsor>
      <collaborator>Medical Research Council, South Africa</collaborator>
      <collaborator>Aurum Institute</collaborator>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>Texas Tech University Health Sciences Center</collaborator>
      <collaborator>University of KwaZulu</collaborator>
      <collaborator>Perinatal HIV Research Unit of the University of the Witswatersrand</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>C3-RCT</other_id>
    </other_ids>
    <start_date>August 27, 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>February 2022</completion_date>
    <study_first_posted>August 21, 2020</study_first_posted>
    <last_update_posted>June 7, 2021</last_update_posted>
    <locations>
      <location>The Aurum Institute, Tembisa, Gauteng, South Africa</location>
      <location>University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa</location>
      <location>Perinatal HIV Research Unit, Klerksdorp, North West, South Africa</location>
      <location>University of Cape Town, Cape Town, Western Cape, South Africa</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04523090</url>
  </study>
  <study rank="53">
    <nct_id>NCT05195736</nct_id>
    <title>Predicting COVID-19 Patients' Clinical Outcomes Using ICU Mobility Scale and MRC Sum Score</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Barthel index</outcome_measure>
      <outcome_measure>Hospitalization days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Taichung Veterans General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CE21317A#1</other_id>
    </other_ids>
    <start_date>September 16, 2021</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>January 19, 2022</study_first_posted>
    <last_update_posted>February 3, 2022</last_update_posted>
    <locations>
      <location>Taichung Veterans General Hospital, Taichung, Republic Of China(R.O.C), Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05195736</url>
  </study>
  <study rank="54">
    <nct_id>NCT04452669</nct_id>
    <title>VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation</title>
    <acronym>VPCOVID</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in Respiratory Failure</outcome_measure>
      <outcome_measure>Reduction in Cardiac/Circulatory Failure</outcome_measure>
      <outcome_measure>Improvement in Oxygenation</outcome_measure>
      <outcome_measure>Improved Clinical Outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aerogen Pharma Limited</lead_sponsor>
      <collaborator>Ohio State University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>APC-VPCOV-CLN-001</other_id>
    </other_ids>
    <start_date>September 15, 2020</start_date>
    <primary_completion_date>June 29, 2021</primary_completion_date>
    <completion_date>June 29, 2021</completion_date>
    <study_first_posted>June 30, 2020</study_first_posted>
    <last_update_posted>August 5, 2021</last_update_posted>
    <locations>
      <location>Ohio State University, Columbus, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04452669</url>
  </study>
  <study rank="55">
    <nct_id>NCT04854928</nct_id>
    <title>Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LTX-109 gel, 3%</intervention>
      <intervention type="Drug">Placebo gel</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2 ) viral load in the deep nasal cavity as measured by the amount of live virus in the samples.</outcome_measure>
      <outcome_measure>Reduction in SARS-CoV-2 viral load in the anterior nasal cavity as measured by the amount of live virus in the samples.</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability by frequency and seriousness of Adverse Events (AE)</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability by intensity of AE</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pharma Holdings AS</lead_sponsor>
      <collaborator>CTC Clinical Trial Consultants AB</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>C21-109-09</other_id>
    </other_ids>
    <start_date>May 3, 2021</start_date>
    <primary_completion_date>February 2022</primary_completion_date>
    <completion_date>May 2022</completion_date>
    <study_first_posted>April 22, 2021</study_first_posted>
    <last_update_posted>September 20, 2021</last_update_posted>
    <locations>
      <location>ClinSmart Sweden AB, Uppsala, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04854928</url>
  </study>
  <study rank="56">
    <nct_id>NCT04406389</nct_id>
    <title>Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)</title>
    <acronym>IMPACT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Enoxaparin sodium</intervention>
      <intervention type="Drug">Unfractionated heparin</intervention>
      <intervention type="Drug">Fondapariniux</intervention>
      <intervention type="Drug">Argatroban</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>30-day mortality</outcome_measure>
      <outcome_measure>Length of Intensive Care Unit (ICU) Stay in Days</outcome_measure>
      <outcome_measure>Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events</outcome_measure>
      <outcome_measure>Number of major and clinically relevant non-major bleeding events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>186</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20-04021936</other_id>
    </other_ids>
    <start_date>October 13, 2020</start_date>
    <primary_completion_date>June 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>May 28, 2020</study_first_posted>
    <last_update_posted>August 2, 2021</last_update_posted>
    <locations>
      <location>Weill Cornell Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04406389</url>
  </study>
  <study rank="57">
    <nct_id>NCT04291053</nct_id>
    <title>The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Huaier Granule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Clinical status assessed according to the official guideline</outcome_measure>
      <outcome_measure>The differences in oxygen intake methods</outcome_measure>
      <outcome_measure>Duration (days) of supplemental oxygenation</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>The mean PaO2/FiO2</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Length of ICU stay (days)</outcome_measure>
      <outcome_measure>Pulmonary function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>550</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TJ-IRB20200205</other_id>
    </other_ids>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>March 2, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04291053</url>
  </study>
  <study rank="58">
    <nct_id>NCT04842435</nct_id>
    <title>Clinical Study in the Treatment of Patients With Moderate Course of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">COVID-globulin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of subjects in the study groups in whom, during the first 7 days after drug administration, one of the following events developed according to the laboratory-instrumental methods or on the basis of a clinical presentation</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>The elimination time of the SARS-CoV-2 virus</outcome_measure>
      <outcome_measure>The median time to clinical improvement on the WHO Ordinal Scale for Clinical Improvement</outcome_measure>
      <outcome_measure>The incidence of severe and extremely severe COVID-19 disease</outcome_measure>
      <outcome_measure>The need for respiratory support</outcome_measure>
      <outcome_measure>The need for invasive mechanical ventilation of the lungs, ECMO</outcome_measure>
      <outcome_measure>Time to cancellation of oxygen support</outcome_measure>
      <outcome_measure>The need to stay at the intensive care unit</outcome_measure>
      <outcome_measure>Duration of fever (≥ 380C), days</outcome_measure>
      <outcome_measure>The dynamics of the decrease in points on the NEWS scale</outcome_measure>
      <outcome_measure>Dynamical CRP, ferritin, D-dimer values</outcome_measure>
      <outcome_measure>Changes in the degree of lung lesion determined by the CT</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Microgen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>376</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGK-P-II/III-00-003/2020</other_id>
    </other_ids>
    <start_date>April 12, 2021</start_date>
    <primary_completion_date>September 30, 2021</primary_completion_date>
    <completion_date>October 5, 2021</completion_date>
    <study_first_posted>April 13, 2021</study_first_posted>
    <last_update_posted>May 14, 2021</last_update_posted>
    <locations>
      <location>15. Municipal Autonomous Institution &quot;Central City Clinical Hospital No. 24&quot;, Ekaterinburg, Russian Federation</location>
      <location>9. State Autonomous Healthcare Institution &quot;Professor A. F. Agafonov Republican Clinical Infectious Hospital&quot;, Kazan, Russian Federation</location>
      <location>13. State Budgetary Healthcare Institution &quot;Specialized Clinical Infectious Diseases Hospital&quot; of the Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation</location>
      <location>6. State Budgetary Healthcare Institution &quot;Scientific and Research Institute Professor S. V. Ochapovskiy Territorial Clinical Hospital&quot; of the Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation</location>
      <location>1. State Budgetary Institution of Healthcare of Moscow &quot;City Clinical Hospital No. 40 of the Moscow Department of Health&quot;, Moscow, Russian Federation</location>
      <location>14. State Budgetary Institution of Healthcare of Moscow &quot;Infectious Clinical Hospital No. 2&quot; of the Moscow Department of Health, Moscow, Russian Federation</location>
      <location>16. State Budgetary Institution of Healthcare of Moscow &quot;Infectious Clinical Hospital No. 1&quot; of the Moscow Department of Health, Moscow, Russian Federation</location>
      <location>18. State Budgetary Institution of Healthcare of Moscow &quot;City Clinical Hospital No. 52 of the Moscow Department of Health&quot;, Moscow, Russian Federation</location>
      <location>19. State Budgetary Institution of Healthcare of Moscow &quot;City Clinical Hospital of V.P. Demikhova of the Moscow Department of Health&quot;, Moscow, Russian Federation</location>
      <location>20. State Budgetary Institution of Healthcare of Moscow &quot;Scientific and Research Institute of N.V. Sklifosovskiy of the Moscow Department of Health&quot;, Moscow, Russian Federation</location>
      <location>21. State Budgetary Institution of Healthcare of Moscow &quot;City Clinical Hospital No. 4 of the Moscow Department of Health&quot;, Moscow, Russian Federation</location>
      <location>3. State Budgetary Healthcare Institution of Moscow &quot;City Clinical Hospital No. 24 of the Moscow Department of Health&quot;, Moscow, Russian Federation</location>
      <location>7. Federal State Budgetary Institution &quot;Central Clinical Hospital with an Outpatient Facility&quot; of the Administrative Directorate of the President of the Russian Federation, Moscow, Russian Federation</location>
      <location>4. Federal State Budgetary Educational Institution of Higher Education &quot;Orenburg State Medical University&quot; of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation</location>
      <location>10. Federal State Budgetary Educational Institution of Higher Education &quot;Academician I. P. Pavlov Ryazan State Medical University&quot; of the Ministry of Health of the Russian Federation, Ryazan', Russian Federation</location>
      <location>5. Saint Petersburg State Budgetary Healthcare Institution &quot;City Hospital No. 40 of the Kurortny Region&quot;, Saint Petersburg, Russian Federation</location>
      <location>12. Federal State Budgetary Educational Institution of Higher Education &quot;Samara State Medical University&quot; of the Ministry of Health of the Russian Federation, Samara, Russian Federation</location>
      <location>11. Regional State Budgetary Healthcare Institution &quot;Clinical Hospital No. 1&quot;, Smolensk, Russian Federation</location>
      <location>17. Federal State Budgetary Educational Institution of Higher Education &quot;Bashkiria State Medical University&quot; of the Ministry of Health of the Russian Federation, Ufa, Russian Federation</location>
      <location>8. State Budgetary Healthcare Institution of the Yaroslavl Region &quot;Yaroslavl Regional Clinical Hospital of War Veterans - International Center for Problems of the Elderly &quot;Zdorovoye Dolgoletiye&quot;, Yaroslavl, Russian Federation</location>
      <location>2. State Budgetary Institution of Healthcare of the Moscow Region &quot;Zhukovskiy City Clinical Hospital&quot;, Zhukovskiy, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04842435</url>
  </study>
  <study rank="59">
    <nct_id>NCT04780672</nct_id>
    <title>Clinical Study in the Treatment of Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Molixan</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>WHO Ordinal Scale for Clinical Improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Time to cancellation of oxygen support</outcome_measure>
      <outcome_measure>Invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Stay in the intensive care unit</outcome_measure>
      <outcome_measure>The transition of the disease to an extremely severe course</outcome_measure>
      <outcome_measure>Fever</outcome_measure>
      <outcome_measure>The dynamics of the National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>The dynamics of changes in the level of C-reactive protein</outcome_measure>
      <outcome_measure>The dynamics of residual symptoms</outcome_measure>
      <outcome_measure>The dynamics of blood biochemical parameters</outcome_measure>
      <outcome_measure>The dynamics of CT signs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pharma VAM</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MNCV-III/2-2020</other_id>
    </other_ids>
    <start_date>March 9, 2021</start_date>
    <primary_completion_date>May 31, 2022</primary_completion_date>
    <completion_date>September 30, 2022</completion_date>
    <study_first_posted>March 3, 2021</study_first_posted>
    <last_update_posted>October 11, 2021</last_update_posted>
    <locations>
      <location>Yaroslavl Regional Clinical Hospital for War Veterans - The International Center for the Elderly &quot;Healthy Longevity&quot;, Yaroslavl, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04780672</url>
  </study>
  <study rank="60">
    <nct_id>NCT04342637</nct_id>
    <title>COVID-19 Endoscopy Survey</title>
    <acronym>COVID-19 Endo</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Practice details</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of GI societies recommendations on prevention of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>To measure the percentage change in performed endoscopic procedure in response to COVID-19</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on procedure time</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on time of disinfection</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on procedure success</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on complications</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on working time</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on staff number</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Al-Azhar University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>WES-2</other_id>
    </other_ids>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>April 25, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>May 20, 2020</last_update_posted>
    <locations>
      <location>Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States</location>
      <location>Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt</location>
      <location>Al-Azhar Univerisity, Cairo, Egypt</location>
      <location>Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342637</url>
  </study>
  <study rank="61">
    <nct_id>NCT04412486</nct_id>
    <title>COVID-19 Convalescent Plasma (CCP) Transfusion</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">COVID Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in PaO2/FiO2 after CCP transfusion.</outcome_measure>
      <outcome_measure>Change in pulse oximetry status after CCP transfusion.</outcome_measure>
      <outcome_measure>Change in aO2 after CCP transfusion.</outcome_measure>
      <outcome_measure>Change in respiratory rate after CCP transfusion.</outcome_measure>
      <outcome_measure>Change in intubation status after CCP transfusion.</outcome_measure>
      <outcome_measure>Change in Sequential Organ Failure Assessment (SOFA).</outcome_measure>
      <outcome_measure>Change in 8-point ordinal clinical deterioration scale.</outcome_measure>
      <outcome_measure>Length of ICU/hospital stay.</outcome_measure>
      <outcome_measure>Development of plasma transfusion reactions.</outcome_measure>
      <outcome_measure>Development of immune complex disorders.</outcome_measure>
      <outcome_measure>Change in anti CoV-2 IgM and IgG levels.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gailen D. Marshall Jr., MD PhD</lead_sponsor>
      <collaborator>University of Mississippi Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2020-0137</other_id>
    </other_ids>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>May 31, 2022</primary_completion_date>
    <completion_date>May 31, 2022</completion_date>
    <study_first_posted>June 2, 2020</study_first_posted>
    <last_update_posted>December 1, 2021</last_update_posted>
    <locations>
      <location>University of Mississippi Medical Center, Jackson, Mississippi, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04412486</url>
  </study>
  <study rank="62">
    <nct_id>NCT05075915</nct_id>
    <title>Transfusion and COVID-19</title>
    <acronym>TRANSCOV-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>7958</other_id>
    </other_ids>
    <start_date>September 1, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>October 13, 2021</study_first_posted>
    <last_update_posted>December 1, 2021</last_update_posted>
    <locations>
      <location>Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05075915</url>
  </study>
  <study rank="63">
    <nct_id>NCT05157217</nct_id>
    <title>Impact of the Genetic Polymorphism on COVID-19 in Egypt</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>ACE I/D gene polymorphism (rs4343)</outcome_measure>
      <outcome_measure>Angiotensin-converting enzyme 2 (ACE2) gene polymorphism (rs908004)</outcome_measure>
      <outcome_measure>Type 2 transmembrane serine protease (TMPRSS2) gene polymorphism (rs12329760)</outcome_measure>
      <outcome_measure>Potential interaction between ACE (I/D), ACE2 and TMPRSS2 gene polymorphisms and the occurrences of severe complications in patients with COVID-19 disease.1</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
      <collaborator>Misr International University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>N-134-2020</other_id>
    </other_ids>
    <start_date>December 2021</start_date>
    <primary_completion_date>February 2022</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>December 14, 2021</study_first_posted>
    <last_update_posted>December 14, 2021</last_update_posted>
    <locations>
      <location>Cairo University Hospitals, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05157217</url>
  </study>
  <study rank="64">
    <nct_id>NCT05184127</nct_id>
    <title>Evaluation of Safety &amp; Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MIR 19 ®</intervention>
      <intervention type="Combination Product">Standard COVID-19 therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Relief of fever</outcome_measure>
      <outcome_measure>Respiratory rate</outcome_measure>
      <outcome_measure>Oxygen saturation</outcome_measure>
      <outcome_measure>Severity of cough</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia</lead_sponsor>
      <collaborator>St. Petersburg Research Institute of Vaccines and Sera</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>156</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SiCoV/KK46- 2021_CSR</other_id>
    </other_ids>
    <start_date>April 27, 2021</start_date>
    <primary_completion_date>September 7, 2021</primary_completion_date>
    <completion_date>September 7, 2021</completion_date>
    <study_first_posted>January 11, 2022</study_first_posted>
    <last_update_posted>January 11, 2022</last_update_posted>
    <locations>
      <location>NRC Institute of Immunology FMBA, Moscow, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05184127</url>
  </study>
  <study rank="65">
    <nct_id>NCT04747769</nct_id>
    <title>COVID-19. CT-Scan Modeling in COVID19 Sequelae</title>
    <acronym>SILICOVILUNG</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Qualitative and quantitative parameters obtained by in silico modeling of intra-pulmonary vascular remodeling in 3D at 2-4 months.</outcome_measure>
      <outcome_measure>Specific mechanical parameters of pulmonary parenchymal stiffness/localized compliances obtained by dynamic poromechanical modeling at 2-4 months.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>APHP210006</other_id>
    </other_ids>
    <start_date>February 3, 2021</start_date>
    <primary_completion_date>October 1, 2021</primary_completion_date>
    <completion_date>October 2021</completion_date>
    <study_first_posted>February 10, 2021</study_first_posted>
    <last_update_posted>August 30, 2021</last_update_posted>
    <locations>
      <location>Hôpital Avicenne APHP, Bobigny, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04747769</url>
  </study>
  <study rank="66">
    <nct_id>NCT04552366</nct_id>
    <title>A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Ad5-nCoV</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of the AE in all groups</outcome_measure>
      <outcome_measure>Seroconversion rate of the IgG antibody against SARS-CoV-2</outcome_measure>
      <outcome_measure>Geomean titers of the IgG antibody against SARS-CoV-2</outcome_measure>
      <outcome_measure>Seroconversion rate of the neutralizing antibody against SARS-CoV-2</outcome_measure>
      <outcome_measure>Geomean titers of the neutralizing antibody against SARS-CoV-2</outcome_measure>
      <outcome_measure>Incidence of Serious adverse events (SAE) in all groups</outcome_measure>
      <outcome_measure>Cellular immune response by ELISpot</outcome_measure>
      <outcome_measure>Geomean titers of neutralizing antibody response to Ad5-vector</outcome_measure>
      <outcome_measure>Cellular immune response by ICS</outcome_measure>
      <outcome_measure>Geomean titers of the IgA antibody against SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China</lead_sponsor>
      <collaborator>Zhongnan Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>149</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>AMMS85-2004</other_id>
    </other_ids>
    <start_date>September 29, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>September 17, 2020</study_first_posted>
    <last_update_posted>December 7, 2020</last_update_posted>
    <locations>
      <location>Zhongnan Hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04552366</url>
  </study>
  <study rank="67">
    <nct_id>NCT04336462</nct_id>
    <title>Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">oxyhydrogen</intervention>
      <intervention type="Device">Oxygen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recovery time</outcome_measure>
      <outcome_measure>Clinical Symptom Remission time</outcome_measure>
      <outcome_measure>fever duration</outcome_measure>
      <outcome_measure>Leicester cough questionaire (LCQ)</outcome_measure>
      <outcome_measure>minimum oxygen</outcome_measure>
      <outcome_measure>Negative conversion rate</outcome_measure>
      <outcome_measure>white blood cell(WBC)</outcome_measure>
      <outcome_measure>Red blood cells(RBC)</outcome_measure>
      <outcome_measure>Hemoglobin(Hb )</outcome_measure>
      <outcome_measure>Platelets(PLT)</outcome_measure>
      <outcome_measure>Lymphocyte count</outcome_measure>
      <outcome_measure>The percentage of lymphocyte</outcome_measure>
      <outcome_measure>neutrophils</outcome_measure>
      <outcome_measure>C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Myocardial enzyme</outcome_measure>
      <outcome_measure>liver function</outcome_measure>
      <outcome_measure>Renal function</outcome_measure>
      <outcome_measure>Muscle enzyme</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Asclepius Meditec Inc.</lead_sponsor>
      <collaborator>Shanghai Public Health Clinical Center</collaborator>
      <collaborator>Henan Provincial People's Hospital</collaborator>
      <collaborator>Shenzhen Third People's Hospital</collaborator>
      <collaborator>The First People's Hospital of Yunnan</collaborator>
      <collaborator>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</collaborator>
      <collaborator>Shanghai 6th People's Hospital</collaborator>
      <collaborator>Guangdong Provincial Hospital of Traditional Chinese Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>JT202002LZ</other_id>
    </other_ids>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>February 21, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336462</url>
  </study>
  <study rank="68">
    <nct_id>NCT04534673</nct_id>
    <title>Pegylated Interferon Lambda for Treatment of COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lambda 180 mcg S.C</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral shedding in days since initial diagnosis</outcome_measure>
      <outcome_measure>Rate of adverse events and severe adverse events</outcome_measure>
      <outcome_measure>Time to clinical recovery</outcome_measure>
      <outcome_measure>Rate of non-invasive or mechanical ventilation</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Undetectable COVID-19 virus levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Soroka University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0129-20-SOR</other_id>
      <other_id>SCRC200006</other_id>
    </other_ids>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>December 31, 2023</primary_completion_date>
    <completion_date>December 31, 2024</completion_date>
    <study_first_posted>September 1, 2020</study_first_posted>
    <last_update_posted>January 28, 2022</last_update_posted>
    <locations>
      <location>Soroka UMC, Be'er Sheva, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04534673</url>
  </study>
  <study rank="69">
    <nct_id>NCT04770467</nct_id>
    <title>A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BRII-196 and BRII-198</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events (AEs)</outcome_measure>
      <outcome_measure>Incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Change from pre-dose baseline in RBC count</outcome_measure>
      <outcome_measure>Change from pre-dose baseline in WBC count</outcome_measure>
      <outcome_measure>Change from pre-dose baseline in Platelets count</outcome_measure>
      <outcome_measure>Change from pre-dose baseline in Hemoglobin result</outcome_measure>
      <outcome_measure>Change from pre-dose baseline in Creatine kinase result</outcome_measure>
      <outcome_measure>Change from pre-dose baseline in Alanine aminotransferase (ALT) result</outcome_measure>
      <outcome_measure>Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8</outcome_measure>
      <outcome_measure>Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19</outcome_measure>
      <outcome_measure>Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization</outcome_measure>
      <outcome_measure>Assessment of PK parameters: maximum serum concentration observed (Cmax)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brii Biosciences, Inc.</lead_sponsor>
      <collaborator>Brii Biosciences Limited</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BRII-196-198-002</other_id>
    </other_ids>
    <start_date>February 2021</start_date>
    <primary_completion_date>October 2022</primary_completion_date>
    <completion_date>October 2022</completion_date>
    <study_first_posted>February 25, 2021</study_first_posted>
    <last_update_posted>June 7, 2021</last_update_posted>
    <locations>
      <location>Investigative Site 1, Hong Kong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04770467</url>
  </study>
  <study rank="70">
    <nct_id>NCT04928430</nct_id>
    <title>Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">XAV-19</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients with an aggravation of COVID-19</outcome_measure>
      <outcome_measure>Change in Clinical parameters : body temperature</outcome_measure>
      <outcome_measure>Change in Clinical parameters : Respiratory rate</outcome_measure>
      <outcome_measure>Change in Clinical parameters : SpO2 at ambiant air</outcome_measure>
      <outcome_measure>Change in Clinical parameters : Supplemental O2</outcome_measure>
      <outcome_measure>Change in severity on Common Terminology Criteria of Adverse Events (CTCAE) scale (version 5.0)</outcome_measure>
      <outcome_measure>Duration of patient's requirement in supplemental O2</outcome_measure>
      <outcome_measure>Duration of aggravation</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Viral status: RT-PCR or RT-qPCR for SARS-CoV-2</outcome_measure>
      <outcome_measure>Proportion of patients referred to Intensive Care Unit (ICU)</outcome_measure>
      <outcome_measure>Proportion of patients with need for mechanical ventilation</outcome_measure>
      <outcome_measure>Survival rates</outcome_measure>
      <outcome_measure>Safety: Occurrence of adverse effects</outcome_measure>
      <outcome_measure>Safety: hypersensitivity or allergy</outcome_measure>
      <outcome_measure>Safety: laboratories abnormalities : white blood cell count</outcome_measure>
      <outcome_measure>Safety: laboratories abnormalities : red blood cell count</outcome_measure>
      <outcome_measure>Safety: laboratories abnormalities : hemoglobin</outcome_measure>
      <outcome_measure>Safety: laboratories abnormalities : platelets</outcome_measure>
      <outcome_measure>Safety: laboratories abnormalities : creatinine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xenothera SAS</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>722</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>XT-2002</other_id>
      <other_id>2020-005979-12</other_id>
    </other_ids>
    <start_date>April 28, 2021</start_date>
    <primary_completion_date>April 1, 2022</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>June 16, 2021</study_first_posted>
    <last_update_posted>November 29, 2021</last_update_posted>
    <locations>
      <location>Multiprofile Hospital for Active Treatment &quot; St. Ekaterina&quot; - Dimitrovgrad - EOOD, COVID Departement, Dimitrovgrad, Bulgaria</location>
      <location>University Multiprofile Hospital for Active Treatment - Plovdiv - AD, COVID Departement, Plovdiv, Bulgaria</location>
      <location>Complex Oncological Center - Ruse Ltd, COVID Departement, Ruse, Bulgaria</location>
      <location>Specialized Hospital for Active Treatment for Pneumophtisiatrics Diseases Dr. Dimitar Gramatikov - Ruse - EOOD, Departement of Pneumology, Ruse, Bulgaria</location>
      <location>5th Multiprofile hospital for Active Treatment - Sofia - EAD, Departement of Pneumology and Phtisiatric, Sofia, Bulgaria</location>
      <location>Evangelismos General Hospital of Athens, Critical Care Departement, Athens, Greece</location>
      <location>&quot;Sotiria&quot; General Hospital of Chest Diseases of Athens, 3rd Department of Medicine of University of Athens, Athens, Greece</location>
      <location>University Hospital of Heraklion, Department of Internal Medicine &amp; Infectious Diseases Unit, Heraklion, Greece</location>
      <location>AHEPA University General Hospital of Thessaloniki, Infectious Diseases Division of 1st Internal Medicine Department, Thessaloniki, Greece</location>
      <location>&quot;Hippokration&quot; General Hospital of Thessaloniki, 3rd Department of Pediatrics, Thessaloniki, Greece</location>
      <location>Leon Daniello Clinical Hospital of Pneumoftiziology, Cluj-napoca, Romania</location>
      <location>Hospital for Infectious Diseases and Pneumology &quot;Victor Babeş&quot; Craiova, Craiova, Romania</location>
      <location>Military Field Hospital ROL-2, Otopeni, Romania</location>
      <location>Pius Brinzeu County Emergency Clinical Hospital Timisoara, Timisoara, Romania</location>
      <location>Ramón y Cajal University Hospital, Madrid, Spain</location>
      <location>Puerta del Hierro University Hospital, Majadahonda, Spain</location>
      <location>Bağcılar Medipol Mega Universite Hastanesi, Bağcılar, Turkey</location>
      <location>Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Fatih, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04928430</url>
  </study>
  <study rank="71">
    <nct_id>NCT04757857</nct_id>
    <title>COVID-19 Antithrombotic Rivaroxaban Evaluation</title>
    <acronym>CARE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivaroxaban 10 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Venous thromboembolic events (VTE)</outcome_measure>
      <outcome_measure>Mechanical ventilation free-survival</outcome_measure>
      <outcome_measure>Major Adverse Cardiovascular Events (MACE)</outcome_measure>
      <outcome_measure>Out-of-hospital death not attributed to major injury</outcome_measure>
      <outcome_measure>Time from randomization to hospitalization</outcome_measure>
      <outcome_measure>Length of Hospitalization</outcome_measure>
      <outcome_measure>Hospitalization in Intensive Care Unit</outcome_measure>
      <outcome_measure>Clinical requirement of mechanical ventilation</outcome_measure>
      <outcome_measure>Clinical duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Composite vascular endpoint I</outcome_measure>
      <outcome_measure>Composite vascular endpoint II</outcome_measure>
      <outcome_measure>Major Bleeding</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Alemão Oswaldo Cruz</lead_sponsor>
      <collaborator>Bayer</collaborator>
      <collaborator>Hospital Israelita Albert Einstein</collaborator>
      <collaborator>Hospital do Coracao</collaborator>
      <collaborator>Hospital Sirio-Libanes</collaborator>
      <collaborator>Hospital Moinhos de Vento</collaborator>
      <collaborator>Brazilian Research In Intensive Care Network</collaborator>
      <collaborator>Brazilian Clinical Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>36066320.5.1001.0070</other_id>
    </other_ids>
    <start_date>September 29, 2020</start_date>
    <primary_completion_date>September 28, 2021</primary_completion_date>
    <completion_date>October 30, 2021</completion_date>
    <study_first_posted>February 17, 2021</study_first_posted>
    <last_update_posted>August 25, 2021</last_update_posted>
    <locations>
      <location>Clínica Senhor do Bonfim, Feira de Santana, Bahia, Brazil</location>
      <location>Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil</location>
      <location>Hospital de Base do Distrito Federal, Brasília, Distrito Federal, Brazil</location>
      <location>Hospital de Campanha Covid-19 Goiânia/Sesgo, Goiânia, Goias, Brazil</location>
      <location>Hospital Estadual de Urgências de Trindade/SESGO, Trindade, Goias, Brazil</location>
      <location>Núcleo de Pesquisa Clínica do Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil</location>
      <location>Hospital São Lucas, Belo Horizonte, Minas Gerais, Brazil</location>
      <location>Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil</location>
      <location>Hospital Universitário Regional de Maringá, Maringá, Paraná, Brazil</location>
      <location>Beneficencia Nipo Brasileira Da Amazonia, Belém, Para, Brazil</location>
      <location>Hospital Adventista de Belém, Belém, Para, Brazil</location>
      <location>Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil</location>
      <location>Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil</location>
      <location>Hospital das Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil</location>
      <location>Hospital Universitario de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil</location>
      <location>Clínica Procárdio Ltda, Blumenau, Santa Catarina, Brazil</location>
      <location>H&amp;W Cardiologia LTDA, Joinville, Santa Catarina, Brazil</location>
      <location>Irmandade santa Casa de Araras, Araras, São Paulo, Brazil</location>
      <location>Alphacor Cardiologia Clínica e Diagnóstica LTDA, Barueri, São Paulo, Brazil</location>
      <location>Maestri e Kormann Consultoria Medico-Cientifica LTDA - EPP, Blumenau, São Paulo, Brazil</location>
      <location>Hospital Regional do Litoral Norte - Instituto Sócrates Guanaes, Caraguatatuba, São Paulo, Brazil</location>
      <location>Hospital Santos Dumont Litoral Norte, Caraguatatuba, São Paulo, Brazil</location>
      <location>Hospital de Corderiopolis, Cordeiropolis, São Paulo, Brazil</location>
      <location>Hospital Regional Jorge Rossman - Instituto Sócrates Guanaes, Itanhaém, São Paulo, Brazil</location>
      <location>Hospital Carlos Fernando Malzoni, Matão, São Paulo, Brazil</location>
      <location>Hospital Moinhos de Vento, Porto Alegre, São Paulo, Brazil</location>
      <location>Hospital Regional de Registro - Instituto Sócrates Guanaes, Registro, São Paulo, Brazil</location>
      <location>Hospital Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil</location>
      <location>Kaiser Clinica e Hospital Dia, São José do Rio Preto, São Paulo, Brazil</location>
      <location>Braile Hospital Dia Ltda, São José Do Rio Preto, São Paulo, Brazil</location>
      <location>Hospital Policlin, São José Dos Campos, São Paulo, Brazil</location>
      <location>Hospital Regional de São José dos Campos - Instituto Sócrates Guanaes, São José Dos Campos, São Paulo, Brazil</location>
      <location>Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil</location>
      <location>International Research Center - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil</location>
      <location>Hospital Leforte Liberdade, São Paulo, Brazil</location>
      <location>Incor - Instituto do Coração do Hospital das Clínicas da FMUSP, São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04757857</url>
  </study>
  <study rank="72">
    <nct_id>NCT04482621</nct_id>
    <title>Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial</title>
    <acronym>DART</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Decitabine</intervention>
      <intervention type="Other">Placebo Saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in clinical state as assessed by a 6-point ordinal scale</outcome_measure>
      <outcome_measure>Safety as assessed by adverse events</outcome_measure>
      <outcome_measure>Change in oxygenation index</outcome_measure>
      <outcome_measure>Change in fraction of inspired oxygen</outcome_measure>
      <outcome_measure>Time (days) to clinical improvement</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Length of stay in hospital</outcome_measure>
      <outcome_measure>Ventilator free days</outcome_measure>
      <outcome_measure>Time to Polymerase chain reaction (PCR) negativity</outcome_measure>
      <outcome_measure>Percentage of patients with National Early Warning Score 2 of 3 or more</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00247544</other_id>
    </other_ids>
    <start_date>September 14, 2020</start_date>
    <primary_completion_date>February 2022</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>July 22, 2020</study_first_posted>
    <last_update_posted>September 28, 2021</last_update_posted>
    <locations>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04482621</url>
  </study>
  <study rank="73">
    <nct_id>NCT04404179</nct_id>
    <title>Setting up a COVID-19 Care Facility at a Prison in Pakistan</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">COVID-19 FACILITY</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recovery</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Services Institute of Medical Sciences, Pakistan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CovJ</other_id>
    </other_ids>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>May 2, 2020</primary_completion_date>
    <completion_date>May 2, 2020</completion_date>
    <study_first_posted>May 27, 2020</study_first_posted>
    <last_update_posted>May 29, 2020</last_update_posted>
    <locations>
      <location>Camp Jail / COVID-19 CARE FACILITY/ SIMS, Lahore, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04404179</url>
  </study>
  <study rank="74">
    <nct_id>NCT04474483</nct_id>
    <title>Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Melatonin</intervention>
      <intervention type="Other">Placebo (Methylcellulose) capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cumulative Incidence of Treatment-Emergent Adverse Events</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>COVID-19 related symptoms</outcome_measure>
      <outcome_measure>Rate of resolution of COVID-19 related symptoms</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>State University of New York at Buffalo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UBMELCOVID19</other_id>
    </other_ids>
    <start_date>November 6, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>July 16, 2020</study_first_posted>
    <last_update_posted>June 11, 2021</last_update_posted>
    <locations>
      <location>University at Buffalo, Buffalo, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04474483</url>
  </study>
  <study rank="75">
    <nct_id>NCT05096091</nct_id>
    <title>International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)</title>
    <acronym>InVITE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>1. To characterize immunogenicity (by measurement of anti-Spike [S] antibody [Ab]) of available COVID-19 vaccines in the overall study population, in each of the countries and in defined subgroups</outcome_measure>
      <outcome_measure>Evaluate duration of immunogenicity</outcome_measure>
      <outcome_measure>Evaluate immunogenicity in predefined subgroups (by age, body mass index [BMI], comorbidities, HIV, breakthrough infection, or evidence of prior infection with SARS-CoV-2).</outcome_measure>
      <outcome_measure>Characterize virus causing breakthrough infections using viral genomic sequencing.</outcome_measure>
      <outcome_measure>Compare immunogenicity between different vaccines.</outcome_measure>
      <outcome_measure>Evaluate infection rates after vaccination.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</collaborator>
      <collaborator>Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)</collaborator>
      <collaborator>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</collaborator>
      <collaborator>Partnership for Research on Ebola Virus in Liberia (PREVAIL)</collaborator>
      <collaborator>University Clinical Research Center, Mali</collaborator>
      <collaborator>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</collaborator>
      <collaborator>Onom Foundation and Liver Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>InVITE 01</other_id>
    </other_ids>
    <start_date>August 16, 2021</start_date>
    <primary_completion_date>August 2024</primary_completion_date>
    <completion_date>February 2025</completion_date>
    <study_first_posted>October 27, 2021</study_first_posted>
    <last_update_posted>January 12, 2022</last_update_posted>
    <locations>
      <location>National Institute for Biomedical Research/Institut National de Recherche Biomédicale (INRB), Gombe, Kinshasa, Congo, The Democratic Republic of the</location>
      <location>Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI), Conakry, Guinea</location>
      <location>National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Jakarta - RSU Kabupaten Tangerang, Tangerang, Indonesia</location>
      <location>Partnership for Research in Vaccines and Infectious Diseases in Liberia (PREVAIL) - Duport Road Health Center, Monrovia, Liberia</location>
      <location>University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali</location>
      <location>LaRed Network, Mexico City, Mexico</location>
      <location>LaRed Network, Monterrey, Mexico</location>
      <location>LaRed Network, Oaxaca, Mexico</location>
      <location>LaRed Network, Tapachula, Mexico</location>
      <location>Onom Foundation and Liver Center, Ulaanbaatar, Mongolia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05096091</url>
  </study>
  <study rank="76">
    <nct_id>NCT04716426</nct_id>
    <title>APT™ T3X on the COVID-19 Contamination Rate</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tetracycline hydrochloride 3%</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 Contamination Rate.</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
      <outcome_measure>Average Number of Adverse Events</outcome_measure>
      <outcome_measure>Days Over Which an Adverse Event Was Reported</outcome_measure>
      <outcome_measure>Other Virus or Bacteria Contamination Rate.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nove de Julho</lead_sponsor>
      <collaborator>Santa Casa de Misericórdia de Porto Alegre</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>4.485.847</other_id>
    </other_ids>
    <start_date>January 28, 2021</start_date>
    <primary_completion_date>March 25, 2021</primary_completion_date>
    <completion_date>March 25, 2021</completion_date>
    <study_first_posted>January 20, 2021</study_first_posted>
    <results_first_posted>April 8, 2021</results_first_posted>
    <last_update_posted>April 8, 2021</last_update_posted>
    <locations>
      <location>Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04716426/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04716426</url>
  </study>
  <study rank="77">
    <nct_id>NCT05069636</nct_id>
    <title>Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Lymphatic OMM</intervention>
      <intervention type="Other">Light Touch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rowan University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO-2021-519</other_id>
    </other_ids>
    <start_date>November 15, 2021</start_date>
    <primary_completion_date>February 28, 2023</primary_completion_date>
    <completion_date>February 28, 2023</completion_date>
    <study_first_posted>October 6, 2021</study_first_posted>
    <last_update_posted>November 10, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05069636</url>
  </study>
  <study rank="78">
    <nct_id>NCT04853069</nct_id>
    <title>Oestrogen Treatment for COVID-19 Symptoms</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Transdermal estradiol gel</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evidence of disease progression for mild cases</outcome_measure>
      <outcome_measure>Evidence of disease progression in hospitalised patients (moderate and severe cases)</outcome_measure>
      <outcome_measure>Hospital mortality</outcome_measure>
      <outcome_measure>Duration of hospital admission</outcome_measure>
      <outcome_measure>Admission to ICU/ HDU facility</outcome_measure>
      <outcome_measure>Need for renal replacement therapy</outcome_measure>
      <outcome_measure>Ventilation</outcome_measure>
      <outcome_measure>Time to being fit for hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hamad Medical Corporation</lead_sponsor>
      <collaborator>Laboratoires Besins International</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MRC-05-099</other_id>
    </other_ids>
    <start_date>May 17, 2021</start_date>
    <primary_completion_date>February 28, 2022</primary_completion_date>
    <completion_date>March 31, 2022</completion_date>
    <study_first_posted>April 21, 2021</study_first_posted>
    <last_update_posted>April 21, 2021</last_update_posted>
    <locations>
      <location>Hamad Medical Corporation, Doha, Qatar</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04853069</url>
  </study>
  <study rank="79">
    <nct_id>NCT05041907</nct_id>
    <title>Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)</title>
    <acronym>PLATCOV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Drug">Monoclonal antibodies</intervention>
      <intervention type="Drug">Ivermectin</intervention>
      <intervention type="Other">No treatment</intervention>
      <intervention type="Drug">Remdesivir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of viral clearance for repurposed drugs</outcome_measure>
      <outcome_measure>Rate of viral clearance of positive control (monoclonal antibodies) over time relative to the negative control</outcome_measure>
      <outcome_measure>Rate of viral clearance for small novel molecule drugs</outcome_measure>
      <outcome_measure>Viral kinetic levels in early COVID-19 disease</outcome_measure>
      <outcome_measure>Number of antiviral treatment arms that show a positive signal (&gt;90% probability of &gt;5% acceleration in viral clearance)</outcome_measure>
      <outcome_measure>Rates of viral clearance by treatment arm, as compared against REGN-COV2 (monoclonal antibody cocktail)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oxford</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>VIR21001</other_id>
    </other_ids>
    <start_date>September 30, 2021</start_date>
    <primary_completion_date>August 2023</primary_completion_date>
    <completion_date>August 2023</completion_date>
    <study_first_posted>September 13, 2021</study_first_posted>
    <last_update_posted>January 28, 2022</last_update_posted>
    <locations>
      <location>Universidade Federal de Minas Gerais, Minas Gerais, Brazil</location>
      <location>Vajira hospital, Bangkok, Thailand</location>
      <location>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand</location>
      <location>Bangplee Hospital, Samut Prakan, Thailand</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05041907</url>
  </study>
  <study rank="80">
    <nct_id>NCT04479358</nct_id>
    <title>Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19</title>
    <acronym>COVIDOSE-2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Other">Standard of Care</intervention>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Recovery</outcome_measure>
      <outcome_measure>Achievement of Recovery</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Hospital Length of Stay</outcome_measure>
      <outcome_measure>Clinical Response: Maximum Temperature (Tmax) Response</outcome_measure>
      <outcome_measure>Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation</outcome_measure>
      <outcome_measure>Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation</outcome_measure>
      <outcome_measure>Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation</outcome_measure>
      <outcome_measure>Clinical Response: Rate of Vasopressor/Inotrope Utilization</outcome_measure>
      <outcome_measure>Clinical Response: Duration of Vasopressor/Inotrope Utilization</outcome_measure>
      <outcome_measure>Clinical Response: Time to Vasopressor/Inotrope Utilization</outcome_measure>
      <outcome_measure>Clinical Response: Duration of Increased Supplemental Oxygen from Baseline</outcome_measure>
      <outcome_measure>Biochemical Response: C-reactive Protein Response Rate</outcome_measure>
      <outcome_measure>Safety: Rate of Secondary Infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>332</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB20-1179</other_id>
    </other_ids>
    <start_date>September 10, 2020</start_date>
    <primary_completion_date>March 1, 2022</primary_completion_date>
    <completion_date>March 1, 2023</completion_date>
    <study_first_posted>July 21, 2020</study_first_posted>
    <last_update_posted>December 2, 2021</last_update_posted>
    <locations>
      <location>University of Chicago Medicine, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04479358</url>
  </study>
  <study rank="81">
    <nct_id>NCT04389658</nct_id>
    <title>Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)</title>
    <acronym>CONDITION</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Prevalence of contagiousness in asymptomatic individuals by PCR</outcome_measure>
      <outcome_measure>Ratio of asymptomatic immunized (IgA/IgM and IgG) population</outcome_measure>
      <outcome_measure>Description of demographic characteristics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Igenomix</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1526</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGX1-COV-XS-20-01</other_id>
    </other_ids>
    <start_date>May 7, 2020</start_date>
    <primary_completion_date>June 10, 2020</primary_completion_date>
    <completion_date>August 25, 2020</completion_date>
    <study_first_posted>May 15, 2020</study_first_posted>
    <last_update_posted>October 9, 2020</last_update_posted>
    <locations>
      <location>Igenomix, Paterna, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04389658</url>
  </study>
  <study rank="82">
    <nct_id>NCT04342689</nct_id>
    <title>The Role of Resistant Starch in COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dietary Supplement containing resistant starch</intervention>
      <intervention type="Dietary Supplement">Placebo Starch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rates of hospitalization for a COVID-19 related complication (Phase 3)</outcome_measure>
      <outcome_measure>Time to clinical recovery (TTCR) (Phase 2)</outcome_measure>
      <outcome_measure>Symptom Severity Score (Phase 2)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2000027887</other_id>
    </other_ids>
    <start_date>June 3, 2020</start_date>
    <primary_completion_date>March 1, 2022</primary_completion_date>
    <completion_date>March 1, 2022</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>September 17, 2021</last_update_posted>
    <locations>
      <location>Yale University, New Haven, Connecticut, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342689</url>
  </study>
  <study rank="83">
    <nct_id>NCT05027464</nct_id>
    <title>Developing and Testing a COVID-19 Vaccination Acceptance Intervention</title>
    <acronym>CoVAcS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Vaccination</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Moving to COVID-19 Vaccine Acceptance Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 Vaccination Status</outcome_measure>
      <outcome_measure>Seasonal Influenza Vaccination Status</outcome_measure>
      <outcome_measure>Survey of Veterans from Intervention and Usual Care who did and did not receive COVID-19 vaccination</outcome_measure>
      <outcome_measure>Qualitative Interview with purposive subset of Veterans from Intervention and Usual Care who did and did not receive COVID-19 vaccination</outcome_measure>
      <outcome_measure>Qualitative Interviews with VA staff and Healthcare Providers</outcome_measure>
      <outcome_measure>Secondary Analysis of VA National Data</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
      <collaborator>VA Bedford Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2500</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>SDR 21-141</other_id>
    </other_ids>
    <start_date>February 15, 2022</start_date>
    <primary_completion_date>July 3, 2023</primary_completion_date>
    <completion_date>September 30, 2023</completion_date>
    <study_first_posted>August 30, 2021</study_first_posted>
    <last_update_posted>January 25, 2022</last_update_posted>
    <locations>
      <location>Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, United States</location>
      <location>San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05027464</url>
  </study>
  <study rank="84">
    <nct_id>NCT04666116</nct_id>
    <title>Changes in Viral Load in COVID-19 After Probiotics</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Dietary supplementation in patients with covid disease admitted to hospital</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral load during the period of admission to the nasopharyngeal smear.</outcome_measure>
      <outcome_measure>Clinical indicators on admission and every 48 hours thereafter</outcome_measure>
      <outcome_measure>Analytical parameters</outcome_measure>
      <outcome_measure>Mobility</outcome_measure>
      <outcome_measure>Microbiome analysis in feces</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital de Sagunto</lead_sponsor>
      <collaborator>Biopolis S.L.</collaborator>
      <collaborator>Laboratorios Heel España</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>96</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HdeSagunto</other_id>
    </other_ids>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>February 2021</completion_date>
    <study_first_posted>December 14, 2020</study_first_posted>
    <last_update_posted>December 16, 2020</last_update_posted>
    <locations>
      <location>Hospital de Sagunto, Sagunto, Valencia, Spain</location>
      <location>Hospital de Sagunto, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04666116</url>
  </study>
  <study rank="85">
    <nct_id>NCT04369820</nct_id>
    <title>C5a Receptor Expression - COVID-19 (C5-COV)</title>
    <acronym>C5-COV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">draw blood</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique Hopitaux De Marseille</lead_sponsor>
      <collaborator>Innate Pharma</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>2020-14</other_id>
      <other_id>IDRCB</other_id>
    </other_ids>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 30, 2020</study_first_posted>
    <last_update_posted>May 4, 2020</last_update_posted>
    <locations>
      <location>Assistance Publique Hôpitaux de Marseille, Marseille, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04369820</url>
  </study>
  <study rank="86">
    <nct_id>NCT04401423</nct_id>
    <title>TXA127 for the Treatment of Severe COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TXA127</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of serum creatinine</outcome_measure>
      <outcome_measure>Number of participants requiring intubation and ventilatory support</outcome_measure>
      <outcome_measure>Change in number of deceased participants</outcome_measure>
      <outcome_measure>Number of participants requiring dialysis</outcome_measure>
      <outcome_measure>Number of participants requiring a vasopressors</outcome_measure>
      <outcome_measure>Change in blood inflammatory markers</outcome_measure>
      <outcome_measure>Percent change in supplemental oxygen requirements</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
      <collaborator>Constant Therapeutics LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AAAT0535</other_id>
    </other_ids>
    <start_date>February 10, 2021</start_date>
    <primary_completion_date>June 10, 2021</primary_completion_date>
    <completion_date>June 10, 2021</completion_date>
    <study_first_posted>May 26, 2020</study_first_posted>
    <last_update_posted>July 29, 2021</last_update_posted>
    <locations>
      <location>Columbia University Irving Medical Center, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04401423</url>
  </study>
  <study rank="87">
    <nct_id>NCT04470557</nct_id>
    <title>Relation Between Lab Finding and COVID-19 Severity</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">D-dimer,CBC.ESR,CRP,</intervention>
      <intervention type="Diagnostic Test">Liver function tests ,serum ferritin and PCR for COVID-19 .</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Estimation of severity of patients with COVID-19 in relation to Laboratory findings.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age/>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>RLCS</other_id>
    </other_ids>
    <start_date>July 15, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>July 14, 2020</study_first_posted>
    <last_update_posted>July 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04470557</url>
  </study>
  <study rank="88">
    <nct_id>NCT04558372</nct_id>
    <title>Genosvid Diagnostic Test for Early Detection of COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">exhaled breath sampling</intervention>
      <intervention type="Other">exhaled breath sampling</intervention>
      <intervention type="Other">exhaled breath sampling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnostic accuracy of electronic nose signal in COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gadjah Mada University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1999</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>1.6/2020</other_id>
    </other_ids>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 12, 2020</primary_completion_date>
    <completion_date>December 12, 2020</completion_date>
    <study_first_posted>September 22, 2020</study_first_posted>
    <last_update_posted>December 29, 2020</last_update_posted>
    <locations>
      <location>RS Bhayangkara Tk I R.Said Soekanto, Jakarta, Indonesia</location>
      <location>Saiful Anwar, Malang, Indonesia</location>
      <location>Dr Sardjito Hospital, Yogyakarta, Indonesia</location>
      <location>Bambanglipuro Hospital, Yogyakarta, Indonesia</location>
      <location>Bhayangkara Tk III Polda DIY, Yogyakarta, Indonesia</location>
      <location>RS Akademik UGM, Yogyakarta, Indonesia</location>
      <location>RSPAU Hardjolukito, Yogyakarta, Indonesia</location>
      <location>RST Tk III Dr Soetarto, Yogyakarta, Indonesia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04558372</url>
  </study>
  <study rank="89">
    <nct_id>NCT05155527</nct_id>
    <title>A Double-blind Randomized Controlled Trial of Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients</title>
    <acronym>IFCOV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ivermectin Tablets</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The rate of SARS-CoV-2 viral clearance</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Progression to severe disease</outcome_measure>
      <outcome_measure>Duration of admission</outcome_measure>
      <outcome_measure>Oxygen requirement</outcome_measure>
      <outcome_measure>Proportions of SARS-CoV-2 viral clearance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mahidol University</lead_sponsor>
      <collaborator>Prince of Songkla University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CREC067/64BR-MED46</other_id>
    </other_ids>
    <start_date>December 2021</start_date>
    <primary_completion_date>June 2022</primary_completion_date>
    <completion_date>June 2022</completion_date>
    <study_first_posted>December 13, 2021</study_first_posted>
    <last_update_posted>December 13, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05155527</url>
  </study>
  <study rank="90">
    <nct_id>NCT04587323</nct_id>
    <title>VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Laboratory Assays</outcome_measure>
      <outcome_measure>VEGF-A</outcome_measure>
      <outcome_measure>VEGF-C</outcome_measure>
      <outcome_measure>VEGF-D</outcome_measure>
      <outcome_measure>Tie-2</outcome_measure>
      <outcome_measure>Flt-1</outcome_measure>
      <outcome_measure>PlGF</outcome_measure>
      <outcome_measure>FGF</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB-300005378</other_id>
    </other_ids>
    <start_date>May 22, 2020</start_date>
    <primary_completion_date>March 20, 2023</primary_completion_date>
    <completion_date>May 20, 2023</completion_date>
    <study_first_posted>October 14, 2020</study_first_posted>
    <last_update_posted>November 23, 2021</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham, Birmingham, Alabama, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04587323</url>
  </study>
  <study rank="91">
    <nct_id>NCT05157269</nct_id>
    <title>Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Dietary Supplement">Vitamin Super-B Complex</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to sustained COVID-19 Recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM08-3011</other_id>
    </other_ids>
    <start_date>January 2022</start_date>
    <primary_completion_date>March 2022</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>December 14, 2021</study_first_posted>
    <last_update_posted>December 14, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05157269</url>
  </study>
  <study rank="92">
    <nct_id>NCT04392141</nct_id>
    <title>Colchicine Plus Phenolic Monoterpenes to Treat COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Standard Treatment</intervention>
      <intervention type="Drug">Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality Rate</outcome_measure>
      <outcome_measure>SpO2</outcome_measure>
      <outcome_measure>Length of Hospitalization</outcome_measure>
      <outcome_measure>Lymphocyte Count</outcome_measure>
      <outcome_measure>Serum Lactate Dehydrogenase</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kermanshah University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1399.062</other_id>
    </other_ids>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>November 1, 2020</primary_completion_date>
    <completion_date>November 1, 2020</completion_date>
    <study_first_posted>May 18, 2020</study_first_posted>
    <results_first_posted>April 20, 2021</results_first_posted>
    <last_update_posted>April 20, 2021</last_update_posted>
    <locations>
      <location>Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT04392141/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT04392141/SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04392141</url>
  </study>
  <study rank="93">
    <nct_id>NCT04418284</nct_id>
    <title>Online Learning of Veterinary Anatomy During COVID-19 Pandemic</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Measure the students' interest in studying anatomy on-line.</outcome_measure>
      <outcome_measure>Assess the easiness of using technology during studying anatomy online</outcome_measure>
      <outcome_measure>Assess the student satisfaction regarding the provided study materials</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>South Valley University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>17 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1517</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>2-2020</other_id>
    </other_ids>
    <start_date>June 5, 2020</start_date>
    <primary_completion_date>November 5, 2020</primary_completion_date>
    <completion_date>November 5, 2020</completion_date>
    <study_first_posted>June 5, 2020</study_first_posted>
    <last_update_posted>March 16, 2021</last_update_posted>
    <locations>
      <location>South Valley University, Qinā, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04418284</url>
  </study>
  <study rank="94">
    <nct_id>NCT04449718</nct_id>
    <title>Vitamin D Supplementation in Patients With COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Length of hospitalization</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Number of cases admitted to Intensive Care Unit (ICU)</outcome_measure>
      <outcome_measure>Length of use of mechanic ventilator</outcome_measure>
      <outcome_measure>Number and severity of symptoms</outcome_measure>
      <outcome_measure>Inflammatory markers</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>Vitamin D</outcome_measure>
      <outcome_measure>Creatinine</outcome_measure>
      <outcome_measure>Calcium</outcome_measure>
      <outcome_measure>Physical activity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Sao Paulo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>30959620.4.0000.0068</other_id>
    </other_ids>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>October 7, 2020</primary_completion_date>
    <completion_date>October 7, 2020</completion_date>
    <study_first_posted>June 29, 2020</study_first_posted>
    <last_update_posted>November 17, 2020</last_update_posted>
    <locations>
      <location>Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04449718</url>
  </study>
  <study rank="95">
    <nct_id>NCT05107440</nct_id>
    <title>BREATHE: Virtual Self-management for Long COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">BREATHE</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Self-efficacy to manage symptoms</outcome_measure>
      <outcome_measure>Self-efficacy to manage daily activities</outcome_measure>
      <outcome_measure>Self-efficacy to manage emotions</outcome_measure>
      <outcome_measure>Fatigue severity (FACIT-F)</outcome_measure>
      <outcome_measure>Medical Research Council (MRC) breathlessness scale grade</outcome_measure>
      <outcome_measure>Post-COVID-19 Functional Scale (PCFS) grade</outcome_measure>
      <outcome_measure>Recovery grade</outcome_measure>
      <outcome_measure>Physical functioning subscale score</outcome_measure>
      <outcome_measure>Role limitations due to physical health subscale score</outcome_measure>
      <outcome_measure>Role limitations due to emotional problems subscale score</outcome_measure>
      <outcome_measure>Emotional well-being subscale score</outcome_measure>
      <outcome_measure>Social functioning subscale score</outcome_measure>
      <outcome_measure>Energy/fatigue subscale score</outcome_measure>
      <outcome_measure>Pain subscale score</outcome_measure>
      <outcome_measure>General health subscale score</outcome_measure>
      <outcome_measure>Physical component score</outcome_measure>
      <outcome_measure>Mental component score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Calgary</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>REB21-1359</other_id>
    </other_ids>
    <start_date>October 25, 2021</start_date>
    <primary_completion_date>April 30, 2022</primary_completion_date>
    <completion_date>October 31, 2022</completion_date>
    <study_first_posted>November 4, 2021</study_first_posted>
    <last_update_posted>November 4, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05107440</url>
  </study>
  <study rank="96">
    <nct_id>NCT04978233</nct_id>
    <title>The Opal - COVID-19 Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the acceptability of the Opal app for COVID-19</outcome_measure>
      <outcome_measure>Change in the usability of the Opal app for COVID-19</outcome_measure>
      <outcome_measure>Contact with the healthcare team</outcome_measure>
      <outcome_measure>Change in symptoms</outcome_measure>
      <outcome_measure>Patient satisfaction with scheduled teleconsultations</outcome_measure>
      <outcome_measure>Change in vital signs temperature</outcome_measure>
      <outcome_measure>Change in vital signs respiration rate</outcome_measure>
      <outcome_measure>Change in vital signs oxygen saturation</outcome_measure>
      <outcome_measure>Change in vital signs heart rate</outcome_measure>
      <outcome_measure>Change in vital signs blood pressure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr. Bertrand Lebouche</lead_sponsor>
      <collaborator>McGill University Health Centre/Research Institute of the McGill University Health Centre</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2021-6763</other_id>
    </other_ids>
    <start_date>December 8, 2020</start_date>
    <primary_completion_date>March 31, 2021</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>July 27, 2021</study_first_posted>
    <last_update_posted>July 27, 2021</last_update_posted>
    <locations>
      <location>Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04978233</url>
  </study>
  <study rank="97">
    <nct_id>NCT05157243</nct_id>
    <title>Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Dietary Supplement">Vitamin Super-B Complex</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of participants progressing to severe COVID-19 or death from any cause</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM08-3010</other_id>
    </other_ids>
    <start_date>January 2022</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>May 2022</completion_date>
    <study_first_posted>December 14, 2021</study_first_posted>
    <last_update_posted>December 14, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05157243</url>
  </study>
  <study rank="98">
    <nct_id>NCT05092581</nct_id>
    <title>COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">casirivimab+imdevimab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Concentrations of casirivimab+imdevimab in serum over time</outcome_measure>
      <outcome_measure>Proportion of patients with treatment-emergent serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Proportion of patients with infusion-related reactions</outcome_measure>
      <outcome_measure>Proportion of patients with hypersensitivity reactions</outcome_measure>
      <outcome_measure>Incidence of anti-drug antibodies (ADA) to casirivimab+imdevimab over time</outcome_measure>
      <outcome_measure>Incidence of neutralizing antibodies (NAb) to casirivimab+imdevimab over time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Regeneron Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>17 Years</max_age>
    <max_age/>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R10933-10987-COV-2114</other_id>
      <other_id>2021-004535-84</other_id>
    </other_ids>
    <start_date>December 20, 2021</start_date>
    <primary_completion_date>June 9, 2023</primary_completion_date>
    <completion_date>June 9, 2023</completion_date>
    <study_first_posted>October 25, 2021</study_first_posted>
    <last_update_posted>October 25, 2021</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT05092581</url>
  </study>
  <study rank="99">
    <nct_id>NCT04324489</nct_id>
    <title>DAS181 for Severe COVID-19: Compassionate Use</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAS181</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improved clinical status</outcome_measure>
      <outcome_measure>Return to room air</outcome_measure>
      <outcome_measure>SARS-CoV-2 RNA</outcome_measure>
      <outcome_measure>Discharge</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Renmin Hospital of Wuhan University</lead_sponsor>
      <collaborator>Ansun Biopharma, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DAS181-SARS-CoV-2</other_id>
    </other_ids>
    <start_date>March 6, 2020</start_date>
    <primary_completion_date>April 16, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>May 5, 2020</last_update_posted>
    <locations>
      <location>Renmin Hospital of Wuhan University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324489</url>
  </study>
  <study rank="100">
    <nct_id>NCT04370262</nct_id>
    <title>Multi-site Adaptive Trials for COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOC + Intravenous Famotidine</intervention>
      <intervention type="Drug">SOC + Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Virologic response to study treatment detected in blood</outcome_measure>
      <outcome_measure>Virologic clearance in nasal swab and/or lower respiratory secretions</outcome_measure>
      <outcome_measure>Clinical Severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Northwell Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age/>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>233</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20-0268</other_id>
    </other_ids>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>September 7, 2020</primary_completion_date>
    <completion_date>September 7, 2020</completion_date>
    <study_first_posted>April 30, 2020</study_first_posted>
    <last_update_posted>December 11, 2020</last_update_posted>
    <locations>
      <location>Southside Hospital, Bay Shore, New York, United States</location>
      <location>North Shore University Hospital, Manhasset, New York, United States</location>
      <location>Northern Westchester Hospital, Mount Kisco, New York, United States</location>
      <location>Lenox Hill Hospital, New York, New York, United States</location>
      <location>Long Island Jewish Medical Center, Queens, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04370262</url>
  </study>
</search_results>
